[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"lymphoma-non-hodgkin\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:lymphoma-non-hodgkin":28},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,34,0,25,[9,44,84,115,145,170,194,223,259,280,302,330,356,384,408,434,460,483,504,529,552,578,642,661,685],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100632906","phase-1-a-clinical-study-of-mk-1045-in-people-with-non-hodgkin-lymphoma-mk-1045-008-100632906",false,"NCT07519772","A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)","A Phase 1b\u002F2 Study to Evaluate the Safety and Efficacy of MK-1045 Monotherapy or in Combination With Other Anticancer Agents in Participants With Non-Hodgkin Lymphoma","Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\n* Has disease that has relapsed (disease progression after remission) or is refractory (failure to achieve complete or partial response) to at least 2 prior systemic lines of therapy.\n* Has a histologically confirmed diagnosis of follicular lymphoma (FL) or diffuse large B-cell lymphoma (DLBCL).\n* DLBCL participants only: has progressed after or is ineligible for transplant and chimeric antigen receptor T (cell) (CAR-T) therapy.\n* Has provided tumor tissue sample (archival or newly obtained, if performed per standard of care).\n* Has documented retained expression of cluster of differentiation 19 (CD19) in tumor tissue obtained by biopsy after disease progression on CD19-targeting therapy, if experienced disease progression after prior CD19-targeting therapy.\n* Has well-controlled human immunodeficiency virus (HIV) on antiretroviral therapy if has a history of HIV infection.\n* Has undetectable hepatitis B virus (HBV) viral load and received and will continue to receive HBV antiviral therapy if hepatitis B surface antigen (HBsAg)-positive.\n* Has undetectable hepatitis C virus (HCV) viral load and received HCV antiviral therapy if has a history of HCV infection.\n* Has radiographically measurable disease per Lugano Response Criteria.\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Has received a solid organ transplant.\n* Had or has clinically relevant central nervous system (CNS) diseases.\n* Has a history of serious cardiovascular or cerebrovascular diseases.\n* Had prior allogenic stem cell transplantation with acute graft-versus-host-disease (GVHD); has ongoing evidence of chronic GVHD manifesting as skin involvement, diarrhea, or increased serum bilirubin; or requires systemic immunosuppression for GVHD.\n* Is HIV-infected with a history of Kaposi's sarcoma and\u002For Multicentric Castleman's Disease.\n* Has received a live or live-attenuated vaccine within 30 days of randomization.\n* Has received prior CAR-T therapy within 3 months before the first dose of the study intervention.\n* Has a known additional malignancy that is progressing or required active treatment within the past 2 years.\n* Has known active CNS lymphoma or involvement.\n* Has active autoimmune disease that required systemic treatment in the past 2 years.\n* Has active infection requiring systemic therapy.\n* Has a history of severe bleeding disorders.\n* Has not recovered from major surgery or has ongoing surgical complications.\n* Has diagnosis of primary mediastinal B-cell lymphoma.","ALL","18 Years",{"count":20,"type":21},200,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","Researchers are looking for new ways to treat 2 types of non-Hodgkin lymphoma (NHL) called follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). FL is a slow-growing type of NHL. DLBCL is a fast-growing type of NHL. NHL is a cancer in the lymphatic system that causes swollen lymph nodes. The lymphatic system is part of the immune system.\n\nIn this study, researchers want to learn if MK-1045 can treat FL and DLBCL. MK-1045 is a study treatment that is an immunotherapy, which helps the immune system fight cancer.\n\nThe goals of this study are to learn how safe MK-1045 is and if people tolerate it. Researchers also want to see if FL and DLBCL respond (the cancer gets smaller or goes away) to treatment.",[28,29,30],"Lymphoma, Non-Hodgkin","Lymphoma, Follicular","Lymphoma, Large B-Cell, Diffuse","RECRUITING","2026-07-01",{"date":34,"type":35},"2026-07-02","ACTUAL",{"date":37,"type":35},"2026-05-03",{"date":39,"type":21},"2031-04-01",{"name":41,"class":42},"Merck Sharp & Dohme LLC","INDUSTRY",13,{"id":45,"slug":46,"hasResults":12,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":12,"sex":17,"minAge":51,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":56,"conditions":57,"keywords":68,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":83},"100473255","phase-1-cd19cd22-bicistronic-chimeric-antigen-receptor-car-t-cells-in-children-and-young-adults-with-recurrent-or-refractory-b-cell-malignancies-100473255","NCT05442515","CD19\u002FCD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies","Phase 1\u002F2 Dose Escalation Study of CD19\u002FCD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory B Cell Malignancies","* INCLUSION CRITERIA:\n* Diagnosis\n\n  * Participant must:\n\n    * Have pathology confirmed B cell ALL (not isolated to the testis or CNS), CML with ALL transformation, or high-grade lymphoma (e.g., Burkitt's lymphoma, B-lymphoblastic lymphoma, diffuse large B-cell lymphoma, inclusive of low-grade lymphoma that has transformed to high grade disease); and\n    * Have relapsed or been refractory after at least one standard chemotherapy regimen and at least one salvage treatment. Participants with Philadelphia chromosome + ALL must have failed prior tyrosine kinase inhibitor; and\n    * Be ineligible for allogeneic stem cell transplant (SCT), have refused SCT, or have recurred after SCT; and\n    * Be unable to access (in a timely manner), ineligible for, or have relapsed\u002Ffailed after or not responded to a commercially available CD19 CAR T-cell construct; and\n  * Have evidence of at least minimal residual disease or PET-avid disease (lymphoma) at the time of enrollment.\n* CD22\u002FCD19 expression\n\n  * Cohorts A1b, B1b, C2b\n\n    * CD19 must be detected on \\>15% of the malignant cells by immunohistochemistry or \\> 80% by flow cytometry.\n    * CD22 positivity must be confirmed.\n  * Cohorts D1b, 2 B-ALL\n\n    * CD19 or CD22 positivity must be confirmed\n    * Age \\>= 3 years of age and \\\u003C=39 years of age at time of enrollment.\n    * Clinical Performance status: Participants \\>= 16 years of age: Karnofsky \\>= 50%; Participants \\\u003C 16 years of age: Lansky scale \\>= 50%.\n* Participants must have adequate organ and marrow function as defined below:\n\n  * leukocytes \\>= 750\u002FmcL\\*\n  * platelets \\>= 50,000\u002FmcL\\*\n  * total bilirubin \\\u003C=2 X ULN (except in the case of participants with documented Gilbert's disease \\> 3x ULN)\n  * AST(SGOT)\u002FALT(SGPT) \\\u003C=10 X institutional upper limit of normal\n  * creatinine \\\u003C= the maximum for age listed in the table below OR\n  * measured creatinine clearance \\>=60 mL\u002Fmin\u002F1.73 m\\^2 for participants with creatinine levels above the max listed below per age.\n\n    * Age (Years) \\\u003C= 5 \u002F Maximum Serum Creatinine (mg\u002FdL) \\\u003C= 0.8\n    * Age (Years) 6 to \\\u003C= 10 \u002F Maximum Serum Creatinine (mg\u002FdL) \\\u003C= 1.0\n    * Age (Years) \\>10 \u002F Maximum Serum Creatinine (mg\u002FdL) \\\u003C= 1.2\n\n      * a participant will not be excluded because of pancytopenia \\>= Grade 3 if it is due to underlying bone marrow involvement by leukemia\n* Central nervous system (CNS) Status\n* Participants with leukemia with CNS 1 and 2 disease are eligible in the absence of exclusion criteria\n* Participants of child-bearing or child-fathering potential must be willing to practice effective birth control from the time of enrollment until 12 months following completion of study treatment for women and for 4 months following completion of study treatment for men.\n* Participants who are breastfeeding or plan to breastfeed must agree to discontinue\u002Fpostpone breastfeeding while on study therapy and until 1 month after the administration of CAR.\n* Cardiac function: Left ventricular ejection fraction \\>= 45% or fractional shortening \\>=28%\n* Pulmonary Function\n\n  * Baseline oxygen saturation \\>92% on room air at rest\n* Ability of participant or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document.\n* Ability and willingness of participant or Legally Authorized Representative (LAR) to co- enroll on 15-C-0028: Follow-up Evaluation for Gene-Therapy Related Delayed Adverse Events after Participation in Pediatric Oncology Branch Clinical Trials.\n\nEXCLUSION CRITERIA:\n\nParticipants meeting any of the following criteria are not eligible for participation in the study:\n\n* Participants with CNS3 disease, progressing neurologic signs\\* of CNS disease, radiologically detected active CNS lymphoma (\\*resolving manifestation or persistent and\u002For irreversible findings from prior CNS involvement (e.g., blindness) is not exclusionary)\n* Hyperleukocytosis (\\>= 50,000 blasts\u002FmicroL)\n* Positive serum or urine beta-HCG pregnancy test performed at screening.\n* Participants will be excluded based on prior therapy if they fail to meet following washout criteria:\n\n  * Therapy: Systemic Chemotherapy, anti-neoplastic agents, antibody- based therapies\n  * Washout\\*: \\>=2 weeks\n  * Exceptions: 6 weeks for clofarabine or nitrosoureas; No washout for prior intrathecal chemotherapy, steroid therapy, hydroxyurea (no dose increases within prior 2 weeks) or ALL maintenance-type chemotherapy (vincristine, 6-mercaptopurine, oral methotrexate, or a tyrosine kinase inhibitor for participants with Ph+ ALL) provided there is recovery from any acute toxic effects\n  * Therapy: Radiation\n  * Washout\\*: \\>=3 weeks\n  * Exceptions: No time restriction with radiation therapy if the volume of bone marrow treated is less than 10% and the participant has measurable\u002Fevaluable disease outside the radiation window\n  * Therapy: Allogeneic Stem Cell Transplant\n  * Washout\\*: \\>= 100 days since SCT; \\>= 30 days since completion of immunosuppression; \\>= 6 weeks since donor lymphocyte infusion (DLI)\n  * Exceptions: Cannot have evidence of active graft-versus-host disease (GVHD) requiring systemic immunosuppression\n  * Therapy: CAR T-Cell Therapy or other Adoptive Cell Therapy\n  * Washout\\*: \\> 30 days post infusion\n\n    * Washout: Time between therapy and apheresis\n* Positive HIV antibodies consistent with active HIV.\n* Positive hepatitis C antibodies or positive Hepatitis B surface antigen (HbsAG) indicative of current\u002Factive HCV\u002FHBV.\n* Active second malignancy other than in situ carcinoma of the cervix, unless the tumor was treated with curative intent at least two years previously and participant is in remission.\n* History of severe, immediate hypersensitivity reaction attributed to compounds of similar chemical or biologic composition to any agents used in study or in the manufacturing of the cells.\n* Uncontrolled, symptomatic, intercurrent illness or social situations that would limit compliance with study requirements or in the opinion of the PI would pose an unacceptable risk to the participant.","3 Years","39 Years",{"count":54,"type":21},130,[24,25],"Background:\n\nAcute lymphoblastic leukemia (ALL) is the most common cancer in children. About 90% of children and young adults who are treated for ALL can now be cured. But if the disease comes back, the survival rate drops to less than 50%. Better treatments are needed for ALL relapses.\n\nObjective:\n\nTo test chimeric antigen receptor (CAR) therapy. CARs are genetically modified cells created from each patient s own blood cells. his trial will use a new type of CAR T-cell that is targeting both CD19 and CD22 at the same time. CD19 and CD22 are proteins found on the surface of most types of ALL.\n\nEligibility:\n\nPeople aged 3 to 39 with ALL or related B-cell lymphoma that has not been cured by standard therapy.\n\nDesign:\n\nParticipants will be screened. This will include:\n\nPhysical exam\n\nBlood and urine tests\n\nTests of their lung and heart function\n\nImaging scans\n\nBone marrow biopsy. A large needle will be inserted into the body to draw some tissues from the interior of a bone.\n\nLumbar puncture. A needle will be inserted into the lower back to draw fluid from the area around the spinal cord.\n\nParticipants will undergo apheresis. Their blood will circulate through a machine that separates blood into different parts. The portion containing T cells will be collected; the remaining cells and fluids will be returned to the body. The T cells will be changed in a laboratory to make them better at fighting cancer cells.\n\nParticipants will receive chemotherapy starting 4 or 5 days before the CAR treatment.\n\nParticipants will be admitted to the hospital. Their own modified T cells will be returned to their body.\n\nParticipants will visit the clinic 2 times a week for 28 days after treatment. Follow-up will continue for 15 years....",[58,59,60,61,62,63,28,64,65,66,67],"B-NHL","B-Non Hodgkin Lymphoma","Acute Lymphocytic Leukemia","Acute Lymphoblastic Leukemia","B-precursor ALL","B-All","Leukemia, Lymphocytic, B Cell","B-Cell Lymphoma","B-Cell Leukemia","Acute Lymphoid Leukemia",[69,70,71,72,73,63,62,61,60,59],"Philadelphia chromosome + ALL","Lymphoma","CD-22 Expressing Tumor","CD-19 expressing tumor","Adoptive Immunotherapy","2026-06-30",{"date":32,"type":35},{"date":77,"type":35},"2022-12-28",{"date":79,"type":21},"2029-07-01",{"name":81,"class":82},"National Cancer Institute (NCI)","NIH",1,{"id":85,"slug":86,"hasResults":12,"nctId":87,"briefTitle":88,"officialTitle":88,"acronym":4,"eligibilityCriteria":89,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":90,"enrollmentInfo":91,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":94,"conditions":95,"keywords":100,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":107,"lastUpdatePostDateStruct":108,"startDateStruct":110,"completionDateStruct":112,"leadSponsor":114,"locationsCount":83},"100261446","biospecimen-procurement-for-center-for-immuno-oncology-immunotherapy-protocols-100261446","NCT02682667","Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols","* INCLUSION CRITERIA:\n\n  1. Diagnosis of cancer, a premalignant\u002Fneoplastic condition or disease (such as an immunodeficiency) that increases the risk of being diagnosed with a cancer or premalignant\u002Fneoplastic condition\n  2. Age \\>=18 years of age\n  3. ECOG performance status of 0-3.\n\n  5\\. Ability and willingness of subject to provide informed consent\n\nAdditional inclusion criteria pertinent only for participants undergoing apheresis\n\n1. Hemoglobin \\>= 8 mg\u002FdL and platelet count \\> 75 K\u002FmicroL\n2. Weight \\>= 48 kg\n3. Central line in place or adequate venous access\n\nEXCLUSION CRITERIA:\n\n1. Active concomitant medical or psychological illnesses that may increase the risk to the subject.\n2. Inability to provide informed consent\n3. Pregnant or breastfeeding women","120 Years",{"count":92,"type":21},500,"OBSERVATIONAL","Background:\n\nCancer has a major impact in the United States and across the world. In 2015, over 1.5 million new cases of cancer were diagnosed in the U.S. Researchers want to study samples from people with cancer or a pre-malignant condition. They hope to develop more effective treatments.\n\nObjective:\n\nTo better understand the biology of malignancies and why certain cancers respond differently to treatment.\n\nEligibility:\n\nAdults at least 18 years old with cancer or a pre-cancerous condition.\n\nDesign:\n\nParticipants will be screened with a medical history, physical exam, and blood tests. Their diagnosis will be confirmed by the NCI Laboratory of Pathology.\n\nParticipants will send tissue blocks or slides from their original tumor biopsy.\n\nAt least once, participants will have a medical history, physical exam, and blood and urine tests.\n\nParticipants may have the following tests. They may have them more than once:\n\nApheresis. A needle in one arm removes blood. Blood is run through a machine and the sample cells are taken out. The rest of the blood is returned by a needle in the other arm.\n\nBone marrow aspiration and biopsy. The hipbone will be numbed. A needle will be put into the hipbone. Bone marrow will be taken out through the needle.\n\nPiece of cancer tissue taken by a needle and syringe.\n\nComputed tomography (CT) scan, magnetic resonance imaging (MRI) and\u002For positron emission tomography (PET) scan or ultrasound to help locate their tumor. For the scans, they lie in a machine that takes pictures.\n\nA small piece of skin removed.\n\nParticipants will be contacted by phone once a year to find out how they are doing.",[96,28,97,98,99],"Multiple Myeloma","Leukemia-Lymphoma, Adult T-Cell","Hodgkin Disease","Non-Small Cell Lung Cancer",[101,102,103,104,105,106],"Apheresis Products","Immunological","Diverse Malignan","Premalignant","Protein","Natural History","2026-06-23",{"date":109,"type":35},"2026-06-24",{"date":111,"type":35},"2016-04-11",{"date":113,"type":21},"2032-12-01",{"name":81,"class":82},{"id":116,"slug":117,"hasResults":12,"nctId":118,"briefTitle":119,"officialTitle":120,"acronym":121,"eligibilityCriteria":122,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":123,"targetDuration":4,"studyType":22,"phases":125,"briefSummary":126,"conditions":127,"keywords":132,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":144},"100600733","phase-1-a-study-of-ly4152199-in-participants-with-previously-treated-b-cell-malignancies-baffrontier-1--100600733","NCT07101328","A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )","BAF_FRontier-1, A First-in-Human, Phase 1 Trial to Assess Safety, Tolerability, and Preliminary Efficacy of LY4152199, a B-cell Activation Factor Receptor (BAFF-R) T-Cell Engager Bispecific Antibody in Adult Participants With Previously Treated B-cell Malignancies","BAF_FRontier-1","Inclusion Criteria:\n\n* Must have a diagnosis of either follicular lymphoma or diffuse large B-cell lymphoma.\n* Must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n* Estimated life expectancy of greater than or equal to (≥)12 weeks as judged by the Investigator.\n* Participants with select tumor types must have measurable or assessable disease as defined below:\n\n  * Participants with lymphoma must have at least 1 bi-dimensionally measurable lesion or in the absence of measurable lymphadenopathy, documentation of bone marrow involvement.\n  * Participants with Waldenstrom macroglobulinemia (WM) must have measurable disease, defined as the presence of serum IgM with a minimum IgM level of greater than (\\>)2 times (×) upper limit of normal (ULN) based on local laboratory testing.\n* Must be able to comply with inpatient\u002Foutpatient treatment, laboratory monitoring, and required clinic visits for the duration of trial participation.\n* Must have adequate organ function.\n\nPhase 1 Dose Escalation (Cohort A) Participants - Must have histologically confirmed relapsed\u002Frefractory B-cell malignancy.\n\nPhase 1 Dose Optimization (Cohort B) Participants\n\n\\- Must have histologically confirmed relapsed\u002Frefractory diffuse large B-cell lymphoma (DLBCL) de novo or transformed from follicular lymphoma (FL).\n\nExclusion Criteria:\n\nAll Participants\n\n* Known or suspected peripheral blood involvement by malignant cells with an absolute lymphocyte count of greater than or equal to (≥) 5000 cells per microliter (μL).\n* Known or suspected central nervous system (CNS) involvement by systemic lymphoma.\n* Current or history of CNS disease, such as stroke, epilepsy, CNS vasculitis, or neurodegenerative disease\n* Any unresolved toxicities from prior therapy greater than National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 Grade 2 at the time of starting trial treatment except for alopecia.\n* Autologous stem cell transplantation within 100 days of this study for post autologous transplant individuals.\n* Residual symptoms of neurotoxicity or cytopenias from prior chimeric antigen receptor T-cell therapy (CAR-T) or bispecifics. Exception: Cytopenia related to prior CAR-T or bispecifics allowed if they meet the adequate organ function criteria.\n* Known or suspected history of macrophage activation syndrome or hemophagocytic lymphohistiocytosis (HLH).\n* Active second malignancies, unless in remission, with life expectancy greater than 2 years with Sponsor approval.\n* History of autoimmune disease\n* Significant cardiovascular disease\n* Active uncontrolled systemic bacterial, viral, fungal, or parasitic infection (except for fungal nail infection), or other clinically significant active disease process\n* Vaccination with a live vaccine within 4 weeks prior to signing informed consent form (ICF).\n* Have current or had a history of severe allergic or anaphylactic reactions to monoclonal antibody therapy (or recombinant antibody-related fusion proteins).\n* Prior treatment with B-cell activating factor receptor (BAFF-R) directed therapies (e.g., monoclonal antibody, CAR-T or bispecific antibody).\n* Pregnant and\u002For planning to breastfeed during the trial or within 90 days of the last dose of study intervention.\n* Known hypersensitivity to any component or excipient of LY4152199.",{"count":124,"type":21},215,[24],"The purpose of this study is to find the best dose of the drug and measure the safety and efficacy of LY4152199 in participants with previously treated B-cell malignancies. Participants will have the option to continue taking LY4152199 until the study ends.",[28,128,30,29,129,130,131],"B-cell Lymphoma","Lymphoma, B-cell Marginal Zone","Waldenstrom Macroglobulinemia","Lymphoma, Mantle Cell",[133,134],"B- cell activating factor receptor (BAFFR)","Bispecific antibody","NOT_YET_RECRUITING","2026-06-19",{"date":107,"type":35},{"date":139,"type":21},"2026-06",{"date":141,"type":21},"2029-09",{"name":143,"class":42},"Eli Lilly and Company",50,{"id":146,"slug":147,"hasResults":12,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":4,"eligibilityCriteria":151,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":152,"targetDuration":4,"studyType":22,"phases":154,"briefSummary":155,"conditions":156,"keywords":157,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":160,"lastUpdatePostDateStruct":161,"startDateStruct":163,"completionDateStruct":165,"leadSponsor":167,"locationsCount":169},"100641130","phase-1-a-study-to-evaluate-safety-and-clinical-activity-of-gsk5926371-in-adult-participants-with-relapsed-or-refractory-b-nhl-100641130","NCT07607925","A Study to Evaluate Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-NHL","A Phase 1\u002F2 Open-label, Multi-center Study to Evaluate the Safety and Clinical Activity of GSK5926371 in Adult Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (B-NHL)","Inclusion Criteria:\n\n* Has histologically confirmed Relapsed\u002FRefractory (R\u002FR) B-NHL, for which systemic treatment is indicated,\n\n  1. Has measurable disease,\n  2. Has received at least 2 prior lines of systemic anti-neoplastic therapy, including an anti-CD20-containing combination appropriate for the indication;\n  3. Has documented disease relapse, progression or disease refractory to the most recent line of therapy, per Lugano criteria.:\n* Willing to use adequate contraception (Participant of childbearing potential \\[POCBP\\] only).\n* Is capable of giving signed informed consent\n* Has an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.\n* Has adequate organ function.\n\nExclusion Criteria:\n\n* Has a malignancy (except disease under study) that has progressed or required active treatment within the past 24 months except for basal cell or squamous cell carcinomas of the skin or in-situ carcinomas (e.g., breast, cervix, bladder) that have been resected with no evidence of metastatic disease.\n* Has had any major surgery within 4 weeks prior to the first dose of GSK5926371 or has not recovered from prior surgeries or complications.\n* Has a history of Progressive multifocal leukoencephalopathy (PML), current central nervous system (CNS) involvement by lymphoma, or a history of significant CNS disease such as uncontrolled seizures, stroke, epilepsy, CNS vasculitis, and neurodegenerative conditions.\n* Has an active uncontrolled infection.\n* Has received a prior Allogeneic stem cell transplant (allo-SCT) within 12 months prior to the first dose of GSK5926371 or has active graft-versus-host disease requiring systemic immunosuppressive therapy.\n* Has received a prior autologous stem cell transplant within 100 days prior to the first dose of GSK5926371.\n* Has received prior treatment with Chimeric antigen receptor T-cell (CAR-T) therapy within 12 weeks of first GSK5926371 administration.\n* Has received prior treatment with CD19- or CD20-targeting Bispecific antibody (BsAbs) within 8 weeks of the first dose of study intervention.\n* Has QT interval corrected (QTc) \\>450 milliseconds (msec) or QTc \\>480 msec for participants with bundle branch block.\n* Has significant cardiovascular disease such as uncontrolled arrhythmias, Class 3 or 4 congestive heart failure as defined by the New York Heart Association Functional Classification, ejection fraction \\\u003C=45% by any methods in the 12 months of enrollment, unstable angina or acute coronary syndrome including myocardial infarction within 6 months of enrollment.",{"count":153,"type":21},49,[24,25],"The goal of this clinical trial is to learn if drug GSK5926371 works to treat a form of B-cell cancer (a type of blood cancer) that has returned or failed to respond to prior therapies in adults. The study will primarily assess the drugs safety and tolerability in participants. Additionally, it seeks to determine the clinical efficacy and pharmacokinetic (PK) properties of GSK5926371.",[28],[158,159],"Relapsed or Refractory B-cell Non-Hodgkin Lymphomas (B-NHL)","GSK5926371","2026-06-17",{"date":162,"type":35},"2026-06-18",{"date":164,"type":21},"2026-06-12",{"date":166,"type":21},"2029-09-24",{"name":168,"class":42},"GlaxoSmithKline",3,{"id":171,"slug":172,"hasResults":12,"nctId":173,"briefTitle":174,"officialTitle":175,"acronym":4,"eligibilityCriteria":176,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":177,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":179,"conditions":180,"keywords":182,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":188,"lastUpdatePostDateStruct":189,"startDateStruct":190,"completionDateStruct":4,"leadSponsor":192,"locationsCount":193},"100184467","tissue-collection-for-studies-of-lymph-cancer-100184467","NCT01676805","Tissue Collection for Studies of Lymph Cancer","Lymphoid Malignancies and Precursors: Tissue Acquisition Protocol","* Lymphoid Malignancies\u002FDiseases:\n\nINCLUSION CRITERIA:\n\n* Patients with a known lymphoid malignancy or precursor disease to a lymphoid malignancy, including multiple myeloma, B-cell and T-cell lymphomas: including but not limited to diffuse large B-cell lymphoma (DLBCL), Hodgkin s lymphoma (HL), multiple myeloma (MM), lymphomatoid granulomatosis (LYG) and adult T-cell leukemia\u002Flymphoma (ATL).\n* Confirmation of pathological diagnosis is required from the Laboratory of Pathology, NCI. Tumor tissue that has been previously collected and is available for study or that can be collected with minimal additional risk to the subject during sampling required for routine patient care or required testing on an NIH research protocol will be used for diagnosis.\n* Age \\>= 18 years of age\n* ECOG performance 0-2\n* Ability of patient or Legally Authorized Representative (LAR) to understand and the willingness to sign a written informed consent document NOTE: Patients enrolling with a LAR must be co-enrolled on another study.\n\nINCLUSION FOR APHERESIS:\n\nNOTE: This is optional in all patients and will only be requested if the patient is willing, timing allows, and the following criteria are met.\n\n* Hemoglobin \\>= 10 mg\u002FdL and platelet count \\> 75 K\u002FuL\n* Weight greater than 25 kg\n* HIV negative\n* Prothrombin Time - within normal limits\n* Partial Thromboplastin Time - within normal limits\n* Medically indicated central line in place or adequate peripheral venous access\n\nEXCLUSION CRITERIA:\n\n* Pregnant individuals will not be eligible.\n* Active symptomatic major organ disorder that would increase the risk of biopsy or apheresis, including but not limited to ischemic heart disease, recent myocardial infarction, active congestive heart failure, pulmonary dysfunction.\n* Active concomitant medical or psychological illnesses that may increase the risk to the subject or inability to obtain informed consent, at the discretion of the principal investigator.\n\nNON-LYMPHOID MALIGNANCIES\u002FDISEASES: The following criteria apply only to patients without a known lymphoid malignancy or precursor disease, as described:\n\nINCLUSION CRITERIA:\n\n-Patients without a known lymphoid malignancy or lymphoid precursor diagnosis who have a planned surgical procedure during which blood or normal lymph node(s)\u002Ftissue (i.e., those not with pre-determined likelihood of abnormality\u002F malignancy) may be obtained for research studies as part of this protocol\n\nPatient is appropriate to undergo the surgical procedure planned, and consented for the same, as needed. NOTE: This study will not evaluate eligibility of the patient for surgery.\n\n* Age \\>= 18 years of age\n* Must be able and willing to sign informed consent\n\nEXCLUSION CRITERIA:\n\n* Pregnant individuals will not be eligible\n* Other active malignancy. NOTE: Patients with a history of curatively treated basal or squamous cell carcinoma or stage 1 melanoma of the skin as well as any in situ carcinoma are eligible. Patients with a malignancy that has been treated with curative intent and who are without evidence of disease for \\>=2 years will also be eligible at the discretion of the investigator.\n* Active concomitant medical or psychological illnesses that may increase the risk to the subject or inability to obtain informed consent, at the discretion of the principal investigator.",{"count":178,"type":21},1295,"Background:\n\n\\- Lab studies help researchers better understand cancer biology. This information may lead to new methods for diagnosing or treating cancer. To develop these studies, researchers want to collect samples from people with cancer or precancer conditions of the lymph system. These conditions include multiple myeloma, different types of lymphoma, and adult leukemia\u002Flymphoma. The samples collected will include blood, urine, bone marrow, and tumor and skin tissue.\n\nObjectives:\n\n\\- To collect tissue samples to study different types of lymph cancer.\n\nEligibility:\n\n\\- Individuals at least 18 years of age who have a lymphoid cancer or precancer condition.\n\nDesign:\n\n* Participants will be screened with a physical exam and medical history.\n* Different samples will be collected for study. Blood samples will be collected at the initial testing. More blood samples will be collected at different treatment points. Other liquid samples include urine, bone marrow, and any abnormal fluid. Tumor tissue and skin tissue biopsies will also be collected for study.\n* Treatment will not be provided as part of this study.",[98,28,96,181,97],"Lymphomatoid Granulomatosis",[183,184,185,186,187,106],"Developing Novel Treatment Approaches","Developing Therapeutic Agents","Analysis of Genetic and Genomic Biology","New Prognostic and Diagnostic Models","Analysis of Cellular and Molecular Biology","2026-06-16",{"date":160,"type":35},{"date":191,"type":35},"2012-09-21",{"name":81,"class":82},2,{"id":195,"slug":196,"hasResults":12,"nctId":197,"briefTitle":198,"officialTitle":199,"acronym":200,"eligibilityCriteria":201,"healthyVolunteers":12,"sex":17,"minAge":202,"maxAge":4,"enrollmentInfo":203,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":205,"conditions":206,"keywords":210,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":216,"completionDateStruct":218,"leadSponsor":220,"locationsCount":169},"100642002","toxin-exposure-and-immune-dysregulation-in-non-hodgkin-lymphoma-100642002","NCT07652580","Toxin Exposure and Immune Dysregulation in Non-Hodgkin Lymphoma","Toxin Exposure and Immune Dysregulation in Non-Hodgkin Lymphoma Across the Military Healthcare System","TOXNHL","Inclusion Criteria:\n\n* Age 4 years old and older with a clinical diagnosis of B-cell NHL.\n* Must be willing to undergo phlebotomy and\u002For skin punch biopsy.\n* Must be willing to undergo whole genome sequencing, which includes return of primary and secondary findings.\n\nExclusion Criteria:\n\n* Has any condition that, in the opinion of the Principal Investigator, contraindicates participation in this study. Examples of situation that may contraindicate participation include but are not limited to a) some cases of cerebral vascular accidents where an individual no longer has the capacity to make their own medical decisions and a conservator or responsible family member is not available and b) an individual has active suicidal ideation and is a danger to themselves at the time of enrollment.\n* Does not have access to health care and primary care clinician.\n* Actively undergoing induction treatment for NHL.","4 Years",{"count":204,"type":21},300,"The goal of this observational cohort study is to learn how toxin and occupational exposures, germline genetic variation, and immune dysregulation relate to B-cell non-Hodgkin lymphoma among active-duty service members and other Military Health System beneficiaries. The main questions are whether specific exposures and germline variants are associated with B-cell NHL subtype, immune dysfunction, and clinical outcomes. Participants will complete exposure and medical-history surveys, provide biospecimens for immune and genomic testing, and may be followed annually for up to 3 years.",[207,208,128,209],"Non-Hodgkin Lymphoma","Lymphoma Non-Hodgkin","Immune Dysregulation",[211,70,212,213],"Immunodeficiency","Exposure","Genetics","2026-06-11",{"date":160,"type":35},{"date":217,"type":35},"2025-05-01",{"date":219,"type":21},"2028-05-01",{"name":221,"class":222},"Henry M. Jackson Foundation for the Advancement of Military Medicine","OTHER",{"id":224,"slug":225,"hasResults":12,"nctId":226,"briefTitle":227,"officialTitle":228,"acronym":229,"eligibilityCriteria":230,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":231,"targetDuration":4,"studyType":22,"phases":233,"briefSummary":234,"conditions":235,"keywords":242,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":258},"100434327","phase-2-faecal-microbiota-transplantation-after-allogeneic-stem-cell-transplantation-100434327","NCT04935684","Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation","Faecal Microbiota Transplantation for Prevention of Graft-versus-host Sisease After Allogeneic Stem Cell Transplantation for Haematological Malignancies","TMF-Allo","Inclusion Criteria:\n\n* Patient aged 18 or over\n* Men and women\n* Patients affiliated with a social-security organization\n* Patients undergoing a myelo-ablative allo-HSCT for a controlled haematologic malignant disease, with peripheral stem cells, whatever the type of donor (except cord blood)\n* Signed and dated informed consent\n\nExclusion Criteria:\n\n* Status of tumor progression at the time of allo-HSCT\n* Inability to understand the protocol (linguistic barrier, cognitive difficulties)\n* Medical history of another progressive cancer or occurrence in the 3 previous years (excluding basal cell carcinoma)\n* Presence of a simultaneous serious and uncontrolled disease (severe cardiac, renal, hepatic or respiratory failure, severe sepsis)\n* Fecal incontinence\n* Participation in another clinical trial studying an allograft procedure including the type of graft, the type of immunosuppression, a preventive or a curative treatment of GvHD, or studying the effectiveness of a FMT in another indication.\n* Pregnant women\n* Patient under guardianship, curatorship or protection of justice",{"count":232,"type":21},150,[25],"The aim of this study is to assess the Fecal Microbiota Transplantation (FMT) efficacy in the prevention of allogeneic hematopoietic stem cell transplantation (allo-HSCT) complications and particularly Graft versus Host Disease (GvHD).\n\nThe hypothesis of this study is that allogeneic FMT may improve outcomes of these patients.",[236,237,238,239,28,240,241],"Acute Leukemia in Remission","Myelodysplastic Syndromes","Myeloproliferative Syndrome","Hodgkin Lymphoma","Myeloma","Chronic Lymphocytic Leukemia",[243,244,245,246,247,248],"Allogeneic hematopoietic stem cell transplantation","Hematologic malignancies","Graft versus Host Disease","Intestinal microbiota","Intestinal dysbiosis","Fecal Microbiota Transplantation","2026-06-08",{"date":251,"type":35},"2026-06-09",{"date":253,"type":35},"2022-12-20",{"date":255,"type":21},"2030-05",{"name":257,"class":222},"University Hospital, Clermont-Ferrand",20,{"id":260,"slug":261,"hasResults":12,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":4,"eligibilityCriteria":265,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":266,"targetDuration":4,"studyType":22,"phases":267,"briefSummary":268,"conditions":269,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":279},"100616632","phase-1-a-study-of-jnj-95566692-in-participants-with-non-hodgkin-lymphoid-malignancies-100616632","NCT07308132","A Study of JNJ-95566692 in Participants With Non-Hodgkin Lymphoid Malignancies","A Phase 1, First-in-Human Study of a Novel CD79bxCD20xCD3 Trispecific Antibody in B-Cell Non-Hodgkin Lymphoid Malignancies (NHLs)","Inclusion Criteria:\n\n* B-cell non-Hodgkin lymphoid malignancies (NHL) according to World Health Organization (WHO) 2022 with relapsed or refractory disease and no other approved therapies available that would be more appropriate in the investigator's judgment. • Participants must have received at least 2 prior lines of therapy including an αCD20 monoclonal antibody containing chemotherapy combination schedule. • Participants who have received at least one prior line of therapy but are not eligible or do not have access to standard second line therapies, such as CAR-T, will be allowed to enroll\n* While on study treatment and for 3 months after the last dose of study treatment, a participant must: not breastfeed or become pregnant; not donate gametes (that is, eggs or sperm) or freeze for future use for the purposes of assisted reproduction; and wear an external condom\n* Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1\n* Participants must have measurable disease as defined by the disease criteria (Lugano criteria)\n* Participants of childbearing potential must have a negative highly sensitive (for example, beta \\[β\\]-human chorionic gonadotropin) pregnancy test at screening and within 24 hours before the first dose of study treatment and agree to further pregnancy tests\n\nExclusion Criteria:\n\n* Known active central nervous system involvement (CNS) or leptomeningeal involvement\n* Prior solid-organ transplantation\n* Malignancy diagnosis other than the disease under study within 1 year prior to the first dose of the study treatment; exceptions are squamous and basal cell carcinoma of the skin, carcinoma in situ of the cervix and any malignancy that is considered cured or has minimal risk of recurrence within 1 year of first dose of the study treatment in the opinion of both the investigator and sponsor's medical monitor\n* Autoimmune or inflammatory disease requiring systemic steroids or other immunosuppressive agents (for example, methotrexate or tacrolimus) within 3 months prior to first dose of study treatment\n* Toxicity from prior anticancer therapy that has not resolved to baseline levels or to Grade less than or equal to (\\\u003C=) 1 (except alopecia, vitiligo, peripheral neuropathy, or Grade \\\u003C=2 endocrinopathies that are stable on hormone replacement)",{"count":54,"type":21},[24],"The purpose of this study is to determine the putative recommended Phase 2 doses (RP2Ds) and optimal dose schedule(s) for JNJ-95566692 as a single agent (Arm A) and in combination with JNJ-87801493 (Arm B) (Part 1: Dose Escalation) and to further characterize the safety and clinical activity of JNJ-95566692 as a single agent (Arm A) and in combination with JNJ-87801493 (Arm B) at the putative RP2D(s) (Part 2: Dose Expansion).",[28],"2026-06-04",{"date":272,"type":35},"2026-06-05",{"date":274,"type":35},"2026-01-20",{"date":276,"type":21},"2028-08-31",{"name":278,"class":42},"Janssen Research & Development, LLC",9,{"id":281,"slug":282,"hasResults":12,"nctId":283,"briefTitle":284,"officialTitle":285,"acronym":4,"eligibilityCriteria":286,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":287,"targetDuration":4,"studyType":22,"phases":289,"briefSummary":290,"conditions":291,"keywords":293,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":295,"startDateStruct":296,"completionDateStruct":298,"leadSponsor":300,"locationsCount":301},"100471652","phase-1-a-study-of-jnj-90014496-in-participants-with-b-cell-non-hodgkin-lymphoma-100471652","NCT05421663","A Study of JNJ-90014496 in Participants With B-Cell Non-Hodgkin Lymphoma","A Phase 1b\u002F2, Multicenter, Open-label, Study of JNJ-90014496, an Autologous CD19\u002FCD20 Bi-specific CAR-T Cell Therapy in Adult Participants With B-cell Non-Hodgkin Lymphoma","Inclusion Criteria:\n\n* Participant must be greater than or equal to (\\>=) 18 years of age, at the time of signing informed consent\n* Tumor must be histologically confirmed cluster of differentiation (CD)19 and\u002For CD20 positive\n* Must meet the indications for each subtype in Phase 1b as specified in protocol and Phase 2 participants must have following: Diagnosis of Large B-cell lymphoma (LBCL), Follicular large B-cell lymphoma (FLBCL), or transformation of indolent lymphoma; Received at least 2 prior lines of systemic therapy; Relapsed or refractory disease defined as 1 or more of the following: Stable disease or Progressive disease (PD) as best response to most recent anti-lymphoma therapy OR disease progression or recurrence after a partial response (PR) or complete response (CR) to most recent anti lymphoma therapy; cohort specific requirements as mentioned in protocol\n* Measurable disease as defined by Lugano 2014 classification\n* Eastern cooperative oncology group (ECOG) performance status of 0 to 2\n\nExclusion Criteria:\n\n* History of symptomatic deep vein thrombosis or pulmonary embolism within six months of apheresis (line associated deep vein thrombosis is allowed)\n* History of stroke, unstable angina, myocardial infarction, congestive heart failure New York Heart Association (NYHA) Class III or IV, severe cardiomyopathy or ventricular arrhythmia requiring medication or mechanical control within 6 months of apheresis\n* History of a seizure disorder, dementia, cerebellar disease or neurodegenerative disorder\n* Known history or prior diagnosis of optic neuritis or other immunologic or inflammatory disease affecting the central nervous system\n* Current active liver or biliary disease (except for Gilbert's syndrome or asymptomatic gallstones)\n* Evidence of active viral or bacterial infection requiring systemic antimicrobial therapy, or uncontrolled systemic fungal infection\n* Diagnosis of Human herpes virus (HHV) 8-positive DLBCL or T cell\u002Fhistiocyte-rich large B-cell lymphoma or Burkitt and high-grade B-cell lymphoma with 11q aberrations (previously Burkitt-like lymphoma) or Richter's transformation or Lymphomatoid granulomatosis or Plasmablastic lymphoma or Waldenstrom's Macroglobulinemia\n* Any prior solid organ or allogeneic stem cell transplantation\n* Autologous stem cell transplant within 12 weeks of apheresis; Prior CAR-T cell therapy within 12 weeks of apheresis",{"count":288,"type":21},439,[24,25],"This is a Phase 1b\u002F2, multicenter, open-label, study of prizloncabtagene autoleucel (prizlo-cel), an autologous dual targeting chimeric antigen receptor (CAR) T-cell therapy targeting both cluster of differentiation (CD) CD20 and CD19, for the treatment of adult participants with relapsed or refractory (r\u002Fr) B-Cell non-Hodgkin lymphoma (B-NHL) or frontline high-risk diffuse large B-cell lymphoma (DLBCL).",[28,292,30],"Lymphoma, B-Cell",[294],"CD20\u002FCD19",{"date":272,"type":35},{"date":297,"type":35},"2022-08-12",{"date":299,"type":21},"2041-07-30",{"name":278,"class":42},32,{"id":303,"slug":304,"hasResults":12,"nctId":305,"briefTitle":306,"officialTitle":306,"acronym":4,"eligibilityCriteria":307,"healthyVolunteers":12,"sex":17,"minAge":308,"maxAge":52,"enrollmentInfo":309,"targetDuration":4,"studyType":22,"phases":310,"briefSummary":311,"conditions":312,"keywords":317,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":322,"lastUpdatePostDateStruct":323,"startDateStruct":324,"completionDateStruct":326,"leadSponsor":328,"locationsCount":83},"100500742","phase-2-alphabeta-t-cell-and-cd19-b-cell-depletion-in-allogeneic-stem-cell-transplantation-in-patients-with-malignant-diseases-100500742","NCT05800210","Alpha\u002FBeta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in Patients With Malignant Diseases","Inclusion Criteria:\n\nA. Children, Adolescents, Young adults (ages 6 months to ≤39 years) with the following diseases may be eligible:\n\ni. ALL\n\n1. ALL high risk including one or more of the following: (t(9;22) or 11q23 chromosomal abnormality, primary induction failure (≤15% blasts at time of registration), mixed phenotype acute leukemia (MPAL), persistent MRD (≥0.01% by flow or persistent abnormal karyotype detected by cytogenetics) or hypodiploidy (≤44 chromosomes)) in first remission\n2. ALL in second remission and beyond\n\nii. AML\n\n1. History of AML induction\u002Freinduction Failure (≤15% blasts at time of registration)\n2. AML in CR1 with poor cytogenetics (i.e., 12p, 5a, -7, FLT3 mutation\u002Fduplication, t(9;11) and others)\n3. AML with persistent minimal residual disease (MRD) in CR1(≥0.01% on flow or persistent abnormal karyotype detected by cytogenetics)\n4. AML CR2 or beyond\n5. AML in refractory relapse but ≤15% bone marrow leukemia blasts\n6. Therapy-related AML\n\niii. Juvenile MyeloMonocytic Leukemia (JMML)\n\n1. JMML in CR1 without CBL mutation\n2. JMML with recurrence of disease with or without CBL mutation\n3. JMML CR2 or beyond\n\niv. Chronic Myeloid Leukemia (CML)\n\n1\\. CML in CR with regard to blast crisis\n\nv. High Risk Myelodysplastic syndrome (MDS)\n\nvi. Lymphoma: Hodgkin (HL) or Non-Hodgkin (NHL)\n\n1. HL or NHL with a history of induction failure\n2. HL or NHL in PR1 or PR2\n3. HL or NHL in CR2 or subsequent remission\n\nB. Subjects must not have more than one active malignancy at the time of enrollment (Subjects with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen \\[as determined by the treating physician and approved by the PI\\] may be included).\n\nC. HLA-matched (5-6\u002F6) sibling donor, matched (8-10\u002F10) unrelated donor available for stem cell donation, haplo-identical related donor (at least one full haplotype must be matched).\n\nD. Karnofsky or Lansky score ≥60% at the time of enrollment. Karnofsky scores must be used for patients \\>16 years of age and Lansky scores for patients ≤16 years of age.\n\nE. Adequate organ function (within 4 weeks of initiation of preparative regimen), defined as:\n\ni. Pulmonary: FEV1, FVC, and corrected DLCO must all be ≥ 60% of predicted by pulmonary function tests (PFTs). For children who are unable to perform for PFTs due to age, the criteria are: no evidence of dyspnea at rest and no need for supplemental oxygen.\n\nii. Renal: Creatinine clearance or radioisotope GFR ≥60 mL\u002Fmin\u002F1.73 m2 or a serum creatinine based on age\u002Fgender\n\niii. Cardiac: Shortening fraction of ≥ 27% by echocardiogram) or ejection fraction of ≥ 50% by echocardiogram or radionuclide scan (MUGA).\n\niv. Hepatic: SGOT (AST) or SGPT (ALT) \\\u003C 5 x upper limit of normal (ULN) for age. Conjugated bilirubin \\\u003C 2.5 mg\u002FdL, unless attributable to Gilbert's Syndrome.\n\nF. Written informed consent obtained from the subject or guardian and the subject agrees to comply with all the study-related procedures.\n\nG. Subjects of childbearing potential (SOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for at least 8 weeks after the last dose of study drug to minimize the risk of pregnancy.\n\nH. Subjects with partners of child-bearing potential must agree to use physician-approved contraceptive methods (e.g., abstinence, condoms, vasectomy) throughout the study and should avoid conceiving children for 8 weeks following the last dose of study drug.\n\nExclusion Criteria:\n\nA. Patients with documented uncontrolled infection\n\nB. Patients who have received allogeneic hematopoietic stem cell transplantation within 6 months, unless being done as a boost.\n\nC. Patients with active ≥Grade 2 aGVHD.\n\nD. Demonstrated lack of compliance with medical care.\n\nE. Females or males of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for at least 8 weeks after the last dose of study drug.\n\nF. Females who are known to be pregnant or breastfeeding.\n\nG. History of any other disease, metabolic dysfunction, clinical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of protocol therapy or that might affect the interpretation of the results of the study or that puts the subject at high risk for treatment complications, in the opinion of the treating physician.\n\nH. Prisoners or subjects who are incarcerated, or subjects who are compulsorily detained for treatment of either a psychiatric or physical illness.","6 Months",{"count":258,"type":21},[25],"This study will assess the safety, efficacy, and feasibility of ⍺\u002Fβ CD3+ T-cell and CD19+ B-cell depletion in allogeneic stem cell transplantation in patients with acute lymphocytic leukemia (ALL), acute myeloid leukemia (AML), juvenile myelomonocytic leukemia (JMML), high risk myelodysplastic syndrome (MDS), chronic myeloid leukemia (CML) and lymphoma. Subjects will receive an allogeneic stem cell transplant that has been depleted of ⍺\u002Fβ CD3+ T-cells and CD19+ B-cells using the Miltenyi CliniMACS Prodigy® system.",[61,313,314,237,315,28,316],"Acute Myeloid Leukemia","Juvenile Myelomonocytic Leukemia","Chronic Myeloid Leukemia","Lymphoma, Hodgkin",[318,319,320,321],"hematologic malignancy","GVHD","stem cell transplantation","graft manipulation","2026-06-02",{"date":270,"type":35},{"date":325,"type":35},"2024-05-03",{"date":327,"type":21},"2028-05",{"name":329,"class":222},"University of Florida",{"id":331,"slug":332,"hasResults":12,"nctId":333,"briefTitle":334,"officialTitle":335,"acronym":336,"eligibilityCriteria":337,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":338,"targetDuration":4,"studyType":22,"phases":340,"briefSummary":342,"conditions":343,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":347,"startDateStruct":349,"completionDateStruct":351,"leadSponsor":353,"locationsCount":355},"100397831","phase-4-clinical-trial-assessing-the-immunogenicity-of-an-anti-pneumococcal-vaccination-strategy-pcv13ppv23-versus-prevenar20-in-adult-patients-treated-for-a-lymphoma-100397831","NCT04460235","Clinical Trial Assessing the Immunogenicity of an Anti-pneumococcal Vaccination Strategy (PCV13+PPV23 Versus PREVENAR20) in Adult Patients Treated for a Lymphoma","Immunogénicité de la Vaccination Anti-pneumococcique (PCV13+PPV23 Versus PREVENAR20) Dans le Lymphome Chez l'Adulte","HEMATOVAC","Inclusion Criteria:\n\n* Patient ≥ 18 year-old.\n* AND medical follow-up in hematology unit\n* AND had received a first course of chemotherapy for diffuse large B cell lymphoma or for follicular lymphoma\n* Life expectancy \\> 6 months.\n* Negative pregnancy test.\n* Having signed the consent form.\n* Having an health insurance.\n\nExclusion Criteria:\n\n* Receiving monoclonal antibodies or biotherapies altering the immune response, other than anti-CD20 antibodies in the chemotherapy protocol.\n* Uncontrolled bacterial, viral or fungal infection less than 7 days.\n* Previous vaccination with PCV13 or PPV23 (unless PCV13 was administered in childhood. The last injection must be performed at least five years ago).\n* Preexisting condition that altered the immune response: splenectomy, HIV, primary or secondary immune deficiency, nephrotic syndrome, sickle cell anemia, autoimmune disorder, solid organ transplantation, immunosuppressive drugs or biotherapy not included in the chemotherapy.\n* Patient who already received chemotherapy for malignancy in the previous 2 years before the inclusion.\n* Major blood clotting disorders preventing intramuscular injection.\n* Medical history of anaphylactic reaction to vaccination.\n* Known allergy to one of the vaccine components.\n* Involvement to another vaccine biomedical research.\n* Protected person.\n* Pregnant women or women of childbearing age without appropriate contraceptive measures.\n* Perfusion of polyvalent immunoglobulins during follow-up.\n* Participants with hypersensitivity to aluminum phosphate, phenol or CRM197 protein, protein derived from Corynebacterium diphtheria.",{"count":339,"type":21},160,[341],"PHASE4","The French Public Health Council recommended pneumococcal vaccination combined strategy for all immunocompromised patients in 2012. This strategy consisted in conjugated 13-valent pneumococcal (PCV13) injection followed 2 months later by polysaccharide 23-valent (PPV23) vaccine injection. In 2024, Health authorities changed guidelines to recommend one injection of PREVENAR20 instead of the 2-vaccine scheme general practitioners are usually in charge of this vaccination. Conjugated pneumococcal vaccine enhances the immunogenicity of the polysaccharide vaccine. Acute leukemia and lymphoma are treated with multiple courses of chemotherapy, impairing the immune system and potentially the response to vaccination. These patients are more at risk for developing pneumococcal invasive diseases than the general population. However, efficacy of pneumococcal vaccination is poorly documented in this setting. We assume that 65% of the patients are non-responders to double compared to 45% for PCV20PREVENAR20 vaccination, according to their anti-pneumococcal immunoglobulin G (Ig) titers and the opsonophagocytic activity (OPA). To assess the immunogenicity of the pneumococcal vaccination combined strategy in adult population of acute leukemia and lymphoma, we will measure anti-pneumococcal serotype-specific IgG titers and OPA at different time-points after completion of the combined vaccine strategy. The primary objective is to assess the immunogenicity of pneumococcal vaccination combined strategy at 3 months after the PCV13 injection (corresponding to 1 month after the end of the combined strategy in cohort A) using Ig G titers and OPA, compared to 3 months post PREVENAR20 (cohort B). At different time points (day 0, 4 weeks post PCV13, and 4 weeks, 3-6 months and 9-12 months post PPV23 and in day 0, 4 weeks post PREVENAR20 and 3 months, 5-8 months and 11-14 months post PREVENAR20, the immunological response to vaccination will be monitored using specific-serotype IgG titers, OPA, and total anti-pneumococcal Ig. We will determine predictive factors of non-response to vaccination by comparing demographic data, biological data and treatment received lymphoma patients. The tolerance and safety of the vaccination strategy will also be assessed in this specific hematological population.",[344,345,28],"Vaccine","Streptococcus Pneumoniae","2026-05-27",{"date":348,"type":35},"2026-05-29",{"date":350,"type":35},"2021-09-07",{"date":352,"type":21},"2029-06",{"name":354,"class":222},"Poitiers University Hospital",7,{"id":357,"slug":358,"hasResults":12,"nctId":359,"briefTitle":360,"officialTitle":361,"acronym":362,"eligibilityCriteria":363,"healthyVolunteers":12,"sex":17,"minAge":364,"maxAge":4,"enrollmentInfo":365,"targetDuration":4,"studyType":22,"phases":367,"briefSummary":368,"conditions":369,"keywords":371,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":346,"lastUpdatePostDateStruct":376,"startDateStruct":377,"completionDateStruct":379,"leadSponsor":381,"locationsCount":383},"100262277","phase-2-tapur-testing-the-use-of-food-and-drug-administration-fda-approved-drugs-that-target-a-specific-abnormality-in-a-tumor-gene-in-people-with-advanced-stage-cancer-100262277","NCT02693535","TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer","Targeted Agent and Profiling Utilization Registry (TAPUR) Study","TAPUR","Inclusion Criteria:\n\n* 12 years of age or older (\\*Restrictions apply. Not all therapies are available for patients \\\u003C18)\n* Histologically-proven locally advanced or metastatic solid tumor, multiple myeloma or B cell non-Hodgkin lymphoma who is no longer benefiting from standard anti-cancer treatment or for whom, in the opinion of the treating physician, no such treatment is available or indicated\n* Performance status 0-2 (Per Eastern Cooperative Oncology Group (ECOG) criteria)\n* Patients must have acceptable organ function as defined below. However, as noted above, drug-specific inclusion\u002Fexclusion criteria specified in the protocol appendix for each agent will take precedence for this and all inclusion criteria:\n\n  1. Absolute neutrophil count ≥ 1.5 x 106\u002Fµl\n  2. Hemoglobin \\> 9.0 g\u002Fdl\n  3. Platelets \\> 75,000\u002Fµl\n  4. Total bilirubin \\\u003C 2.0 mg\u002F dl, except in patients with Gilbert's Syndrome\n  5. Aspartate aminotransferase (AST) serum glutamic-oxaloacetic transaminase (SGOT) and alanine aminotransferase (ALT) serum glutamic-pyruvic transaminase (SGPT) \\\u003C 2.5 x institutional upper limit of normal (ULN) (or \\\u003C 5 x ULN in patients with known hepatic metastases)\n  6. Serum creatinine ≤ 1.5 × ULN or calculated or measured creatinine clearance ≥ 50 mL\u002Fmin\u002F1.73 m2\n* Patients must have disease that can be objectively measured by physical or radiographic exam (per RECIST v1.1 for solid tumor, Lugano criteria for non-Hodgkin lymphoma or International Myeloma Working Group criteria for multiple myeloma), defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions and short axis for nodal lesions) as ≥20 mm with conventional techniques or as ≥10 mm with spiral CT scan, MRI, or a subcutaneous or superficial lesion that can be measured with calipers by clinical exam. For lymph nodes, the short axis must be ≥15 mm. Patient's whose disease cannot be objectively measured by physical or radiographic examination (e.g., elevated serum tumor marker only, bone-only disease without an identifiable soft tissue component, or patients with only assessable non-measurable disease) are NOT eligible.\n* Results must be available from a genomic test or immunohistochemistry (IHC) test for protein expression performed in a Clinical Laboratory Improvement Amendments (CLIA)-certified and College of American Pathologists (CAP)-accredited or New York State accredited (for labs offering services to residents of NY) laboratory. Labs that have registered the test with the NIH Genetic Testing Registry or that provide a report that has been designated as optimized for TAPUR participation are preferred, but not required. The genomic or IHC test used to qualify a patient for participation in TAPUR may have been performed on any specimen of the patient's tumor obtained at any point during the patient's care at the discretion of the patient's treating physician. Genomic assays performed on cell-free DNA in plasma (\"liquid biopsies\") will also be acceptable if the genomic analysis is performed in a laboratory that meets the criteria described above.\n* Ability to understand and the willingness to sign a written informed consent\u002Fassent document.\n* Have a tumor genomic profile for which single agent treatment with one of the FDA approved targeted anti-cancer drugs included in this study has potential clinical benefit based on the criteria described in protocol.\n* For orally administered drugs, the patient must be able to swallow and tolerate oral medication and must have no known malabsorption syndrome.\n* Because of the risks of drug treatment to the developing fetus, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) for the duration of study participation, and for four months following completion of study therapy. Should a woman become pregnant or suspect she is pregnant while participating in this study or if she is the partner of a male participant in this study and becomes pregnant while he is participating in this study, she should inform her or her partner's treating physician immediately as well as her obstetrician. Female study patients who become pregnant must immediately discontinue treatment with any study therapy. Male patients should avoid impregnating a female partner. Male study patients, even if surgically sterilized, (i.e. post-vasectomy) must agree to one of the following: practice effective barrier contraception during the entire study treatment period and for a specified amount of time the last dose of study drug, or completely abstain from sexual intercourse.\n\nNote: TAPUR does not explicitly exclude any type of solid tumor, but the patient must have measurable and evaluable disease per RECIST v1.1.\n\nExclusion Criteria:\n\n* Patients whose disease is not measurable or cannot be assessed by radiographic imaging or physical examination (e.g., elevated serum tumor marker only) are not eligible\n* Patients with primary brain tumors or new, untreated or progressive leptomeningeal metastases are excluded\n* Patients with previously treated brain metastases are eligible, provided that the patient has not experienced a seizure or had a clinically significant change in neurological status within the 3 months prior to registration. All patients with previously treated brain metastases must be clinically stable for at least 1 month after completion of treatment and off steroid treatment for one month prior to study enrollment.\n* Patients with known progressive brain metastases are eligible but additional eligibility criteria apply.\n\nNote: there are additional exclusion criteria that may apply","12 Years",{"count":366,"type":21},4200,[25],"The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug.\n\nNOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact TAPUR@asco.org, or if a patient, your nearest participating TAPUR site (see participating centers).\n\n\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\n\nResults in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org\u002Fnews. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress.\n\n\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*\\*",[28,96,370],"Advanced Solid Tumors",[372,373,374,375],"cancer","off-label","precision medicine","targeted therapy",{"date":348,"type":35},{"date":378,"type":35},"2016-03-14",{"date":380,"type":21},"2028-12-31",{"name":382,"class":222},"American Society of Clinical Oncology",181,{"id":385,"slug":386,"hasResults":12,"nctId":387,"briefTitle":388,"officialTitle":389,"acronym":4,"eligibilityCriteria":390,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":391,"targetDuration":4,"studyType":22,"phases":393,"briefSummary":394,"conditions":395,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":400,"lastUpdatePostDateStruct":401,"startDateStruct":402,"completionDateStruct":404,"leadSponsor":406,"locationsCount":83},"100551311","phase-2-epcoritamab-car-t-cells-for-large-b-cell-lymphomas-100551311","NCT06458439","Epcoritamab-CAR T Cells for Large B-cell Lymphomas","Phase IIa Trial to Evaluate Epcoritamab Administered Before and After CAR-T Cell Therapy in Patients With Relapsed or Refractory Large B-cell Lymphomas","Inclusion Criteria:\n\n* Age \\> 18 years\n* Subject must be able and willing to provide informed consent. In the case where the patient is incapacitated or not otherwise capable, a legally authorized representative (or decision maker when there is not an advanced directive in place) must be willing to provide informed consent on behalf of the patient.\n* Able to comply with the study protocol, in the investigator's judgment\n* ECOG PS of 0 - 2\n* Pathology report confirming eligible diagnosis\n* Documented CD20+ tumor cells on most recent biopsy\n* Patients will have failed to respond to frontline standard of care therapy containing an anthracycline and anti-CD20 antibody\n* Patients will be eligible and consent to be treated with a \"commercially available\" anti-CD19, 4-1BB, CD3zeta CAR-T cell therapy or anti-CD19, CD28, CD3zeta CAR T cell therapy (for example, tisagenlecleucel, lisocabtagene maraleucel, or axicabtagene maraleucel)\n* Patients must have a PET\u002FCT scan (preferred), diagnostic CT scan, or MRI with at least one bi-dimensionally measurable lesion (≥ 1.5 cm for nodal lesions or ≥ 1cm for extra-nodal lesions in largest dimension by low-dose computerized tomography \\[CT\\] scan with FDG-uptake ≥ liver)\n* Adequate laboratory studies\n* Resolution of toxicities from prior therapy to a grade that does not contraindicate trial participation in the opinion of the investigator\n* Ability and willingness to take proper contraceptive precautions\n\nExclusion Criteria:\n\n* Inability or unwillingness of the patient or legally authorized representative (or decision-maker when there is not an advanced directive in place) to provide informed consent.\n* Prior solid organ transplantation\n* Primary central nervous system (CNS) lymphoma or active secondary CNS involvement by lymphoma at screening as confirmed by magnetic resonance imaging (MRI)\u002Fcomputed tomography (CT) scan (brain) or, if clinically indicated, by lumbar puncture.\n* History of autoimmune disease or other diseases resulting in permanent immunosuppression or requiring chronic immunosuppressive therapy (see Exclusion Criteria 5a), with the following exceptions:\n\n  1. Patients with a history of autoimmune-related hypothyroidism on a stable dose of thyroid replacement hormone\n  2. Patients with a history of lymphoma-related immune thrombocytopenic purpura or autoimmune hemolytic anemia in remission may be eligible for this study if approved by the Regulatory Sponsor and Principal Investigator\n  3. Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided all of following conditions are met:\n\n  i. Rash must cover \\\u003C 10% of body surface area ii. Disease is well controlled at baseline and requires only low-potency topical corticosteroid iii. No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or corticosteroids (\\> 20 mg\u002Fday prednisone or equivalent for \\> 2 weeks) within the previous 3 months d. rheumatoid arthritis or similar autoimmune\u002Frheumatic conditions\n* Systemic immunosuppressive medications (including but not limited to cyclophosphamide, azathioprine, methotrexate, thalidomide, and anti-tumor necrosis factor agents). However, the following are permitted:\n\n  1. If receiving glucocorticoid treatment at screening, must be a maximum daily dose of prednisone 10 mg (or equivalent) and a total of no more than 140 mg over the last 14 days prior to the first dose of epcoritamab, unless for disease control.\n  2. Patients who received a single dose of a systemic immunosuppressant medications (e.g., single dose of dexamethasone for nausea or B symptoms) may be enrolled\n  3. The use of inhaled corticosteroids is permitted\n  4. The use of mineralocorticoids for management of orthostatic hypotension is permitted\n  5. The use of physiologic doses of corticosteroids (\\\u003C 20 mg\u002Fday of prednisone or equivalent) for uses such as management of adrenal insufficiency is permitted\n* Known past or current malignancy, other than inclusion diagnoses, except for:\n\n  1. Cervical carcinoma of Stage 1B or less.\n  2. Adequately resected, non-metastatic basal cell or squamous cell skin carcinoma.\n  3. Non-invasive, superficial bladder cancer.\n  4. Prostate cancer with a current PSA level \\\u003C0.1 ng\u002FmL.\n  5. Patients with a malignancy that has been treated with curative intent will also be enrolled if that malignancy is in remission prior to first dose of epcoritamab\n* Known clinically significant cardiovascular disease\n* Patients with the following active infection(s) could have increased risks for toxicity if treated with bispecific antibody therapy, thus patient will be excluded if:\n\n  1. Positive serologic or PCR test results for acute or chronic HBV infection. Patients whose HBV infection status cannot be determined by serologic test results (www.cdc.gov\u002Fhepatitis\u002Fhbv\u002Fpdfs\u002Fserologicchartv8.pdf) must be negative for HBV by PCR to be eligible for study participation. Patients with a history of hepatitis B who are negative for HBV by PCR, will not be excluded but will be placed on suppressive antiviral therapy\n  2. Acute or chronic HCV infection. Patients who are positive for HCV antibody must be negative for HCV by PCR to be eligible for study participation. Patients with a history of hepatitis C who have been adequately treated (negative PCR) will not be excluded.\n  3. Positive serologic or RT-PCR test results for HIV infection.\n* Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at study enrollment, or any major documented infection requiring treatment with IV antibiotics or hospitalization within 2 weeks of enrollment. Empiric or prophylactic antibiotics administered during neutropenia or neutropenic fever without microbiologic evidence of infection do not exclude patients.\n* Clinically significant pulmonary disease (e.g., bronchospasm and\u002For obstructive pulmonary disease) that requires chronic oxygen or corticosteroid use \\> 20 mg mg\u002Fday prednisone or equivalent\n* Uncontrolled seizure disorder\n* Exposure to live or live attenuated vaccine within 4 weeks prior to signing ICF\n* Pregnancy or breast feeding\n* Any serious medical condition or abnormality in clinical laboratory tests that, in the investigator's judgment, precludes the patient's safe participation in and completion of the study, or which could affect compliance with the protocol or interpretation of results",{"count":392,"type":21},31,[25],"This study investigates the feasibility and efficacy of epcoritamab treatment before CAR T cells. This study also investigates if, when patients have residual lymphoma after CAR T cells, epcoritamab can help to effectively treat that lymphoma.",[28,396,397,398,399],"Relapsed Diffuse Large B Cell Lymphoma","Refractory Diffuse Large B-cell Lymphoma","High-grade B-cell Lymphoma","Transformed Indolent Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma","2026-05-22",{"date":346,"type":35},{"date":403,"type":35},"2024-09-24",{"date":405,"type":21},"2027-12",{"name":407,"class":222},"Abramson Cancer Center at Penn Medicine",{"id":409,"slug":410,"hasResults":12,"nctId":411,"briefTitle":412,"officialTitle":413,"acronym":4,"eligibilityCriteria":414,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":415,"targetDuration":4,"studyType":22,"phases":416,"briefSummary":417,"conditions":418,"keywords":421,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":425,"lastUpdatePostDateStruct":426,"startDateStruct":428,"completionDateStruct":430,"leadSponsor":432,"locationsCount":193},"100641004","phase-2-epcoritamab-in-combination-with-r-chop-for-patients-with-aggressive-non-hodgkin-lymphoma-100641004","NCT07588698","Epcoritamab in Combination With R-CHOP for Patients With Aggressive Non-Hodgkin Lymphoma","Epcoritamab in Combination With R-CHOP Debulking in Newly Diagnosed Patients With Aggressive Non-Hodgkin Lymphoma","Inclusion Criteria:\n\n1. Participants must have confirmed CD20-positive aggressive B-cell lymphoma, including de novo or transformed diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS); high-grade B-cell lymphoma with MYC and BCL2 and\u002For BCL6 rearrangement; primary mediastinal large B-cell lymphoma (PMBCL); T-cell\u002Fhistiocyte-rich large B-cell lymphoma (THRLBCL); Epstein-Barr virus-positive DLBCL, NOS; or follicular lymphoma grade 3b.\n2. Measurable disease per Lugano 2014 criteria.\n3. No prior therapy for DLBCL or FL G3B other than corticosteroids or palliative radiotherapy. Of note, a cycle of anthracycline-containing regimen (given as standard of care prior to study enrollment) is allowed, provided that patients will receive a total of six cycles of chemotherapy as part of their treatment plan. Patients who received one cycle of an anthracycline-containing regimen prior to enrollment will proceed directly to Cycle 2 on study.\n4. Age ≥18 years\n5. Participants must have an International Prognostic Index (IPI) score of 2-5.\n6. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2 (Karnofsky ≥ 60%)\n7. Demonstrates adequate organ function as defined below:\n\n   Adequate bone marrow function:\n\n   absolute neutrophil count platelets\n   * 1.0 × 10⁹\u002FLitre (L) (with growth factor use allowed)\n   * 75 × 10⁹\u002FL\n\n   Exceptions:\n\n   Patients may be enrolled despite not meeting the thresholds above if either of the following applies, provided the Absolute Neutrophil Count (ANC) is ≥0.75 × 10⁹\u002FL:\n   1. The patient has received one prior cycle of chemotherapy off study, and cytopenias at Cycle 2, Day 1 of protocol therapy are believed to be due to recent chemotherapy, provided there is evidence of marrow recovery and no other contraindications.\n   2. The patient has documented bone marrow involvement by lymphoma, and cytopenias are believed to be disease-related rather than indicative of poor marrow reserve or unrelated pathology. In such cases, enrollment is permitted at the discretion of the investigator if the patient is otherwise eligible and deemed safe to proceed.\n\n   Adequate hepatic function:\n\n   Total bilirubin\n\n   ≤2 × upper limit of normal (ULN) (unless due to Gilbert's)\n\n   Aspartate aminotransferase (AST) Serum glutamic-oxaloacetic transaminase (SGOT)\n\n   ≤3 × institutional upper limit of normal\n\n   Alanine aminotransferase (ALT) Serum glutamic-pyruvic transaminase (SGPT)\n\n   ≤3 × institutional upper limit of normal\n\n   Adequate renal function:\n\n   As assessed by estimated glomerular filtration rate (eGFR)\n\n   Coagulation:\n\n   Prothrombin time (PT) International Normalized Ratio (INR) and Activated partial thromboplastin time aPTT\n\n   ≤1.5 × ULN, unless receiving anticoagulation therapy\n8. Left ventricular ejection fraction (LVEF) ≥50% by multigated acquisition (MUGA) or echocardiography at screening.\n9. Ability to understand and the willingness to sign a written informed consent document.\n10. .Human immunodeficiency virus (HIV)-infected individuals are eligible if the following criteria are met:\n\n    1. Serum HIV viral load is \\\u003C lower limit of detection (LLD) and controlled with antiretroviral therapy for at least 1 year prior to enrollment, with confirmatory testing at screening;\n    2. CD4 count ≥ 200 cells\u002Fmicroliter (μL) at screening;\n    3. Subject is receiving antiretroviral regimens in accordance with current International Acquired Immunodeficiency Syndrome (AIDS) Society guidelines;\n    4. No evidence of AIDS-defining illnesses (other than lymphoma diagnosis) or active opportunistic infections;\n    5. Antiretroviral therapy does not interfere with study medications.\n11. For participants with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated.\n12. Individuals with a history of hepatitis C virus (HCV) infection must have been treated and cured. For individuals with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load.\n13. Individuals with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\n14. The effects of epcoritamab on the developing human fetus are unknown. For this reason, and because bispecific antibodies may be teratogenic, women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control, or abstinence). Woman with reproductive potential must agree to use adequate contraception during the trial, and for 12 months after the last administration of epcoritamab or according to the local prescribing information of the standard of care (SOC) regimens, whichever is the longest. Adequate contraception is defined as highly effective methods of contraception. Also refer to the local prescribing information for information regarding contraceptive requirements for the SOC regimens.\n15. A woman of childbearing potential must have a negative serum (beta-hCG) pregnancy test at screening and a negative urine pregnancy test before treatment administration on Day 1 of every cycle.\n16. A woman must agree not to donate eggs (ova, oocytes) for the purposes of assisted reproduction during the trial and for 12 months after receiving the last dose of epcoritamab or according to the local prescribing information of the SOC regimens, whichever is the longest.\n17. A man who is sexually active with a woman of childbearing potential and has not had a vasectomy must agree to use a barrier method of birth control, eg, either condom with spermicidal foam\u002Fgel\u002Ffilm\u002Fcream\u002Fsuppository or partner with occlusive cap (diaphragm or cervical\u002Fvault caps) with spermicidal foam\u002Fgel\u002Ffilm\u002Fcream\u002Fsuppository, and all men must also not donate sperm during the trial and for 12 months after receiving the last dose of epcoritamab or according to the local prescribing information of the SoC regimens, whichever is the longest.\n18. Participants must agree not to donate blood for 60 days after receiving the last dose of trial treatment.\n19. Participants must have a treating physician at University of California, San Francisco (UCSF) or Zuckerberg San Francisco General Hospital (ZSFGH), receive study treatment under the supervision of the study Principal Investigator or qualified study sub-investigators at the enrolling site, and be willing to comply with study procedures.\n\nExclusion Criteria:\n\n1. History of severe allergic or anaphylactic reactions to anti-CD20 mAb therapy or known allergy or intolerance to any component or excipient of epcoritamab.\n2. Any prior treatment with a bispecific antibody targeting CD3 and CD20.\n3. Treatment with an investigational drug within 4 weeks or 5 half-lives, whichever is longer, prior to the first dose of epcoritamab.\n4. Requiring immunosuppressive therapy for an ongoing baseline medical condition. For corticosteroids, prednisolone \\>10 mg daily (or equivalent) qualifies as immunosuppressive and thus be excluded for this use. Note: corticosteroids at any dose are permitted for control of lymphoma related symptoms, including during screening, and for any adverse events (AE) management during study.\n5. Vaccination with live vaccines within 28 days prior to the first dose of epcoritamab.\n6. Clinically significant cardiovascular disease, including:\n\n   1. Myocardial infarction within 6 months prior to the first dose of epcoritamab, or unstable or uncontrolled disease\u002Fcondition related to or affecting cardiac function (eg, unstable angina, congestive heart failure New York Heart Association Class III-IV), cardiac arrhythmia (NCI Common Terminology Criteria for Adverse Events (CTCAE) Version 5 Grade 3 or higher), or clinically significant electrocardiogram (ECG) abnormalities\n   2. Screening 12-lead ECG showing a baseline QT Corrected for Heart Rate using Fridericia's Formula (QTcF) \\>470 msec\n   3. Stroke within 6 months prior to first epcoritamab dose\n7. Known active bacterial, viral, fungal, mycobacterial, parasitic, or other infection (excluding fungal infections of nail beds) at trial enrolment or significant infections within 2 weeks prior to the first dose of epcoritamab.\n8. Active hepatitis B Virus (HBV) (Deoxyribonucleic Acid Polymerase Chain Reaction (DNA PCR) -positive) or hepatitis C (Ribonucleic Acid Polymerase Chain Reaction (RNA PCR) -positive infection). Subjects with evidence of prior HBV but who are PCR-negative are permitted in the trial but should receive prophylactic antiviral therapy. Subjects who received treatment for Hepatitis C Virus (HCV) that was intended to eradicate the virus may participate if hepatitis C Ribonucleic acid (RNA) levels are undetectable.\n9. Known past or current malignancy other than inclusion diagnosis, except for:\n\n   1. Cervical carcinoma of Stage 1B or less\n   2. Non-invasive basal cell or squamous cell skin carcinoma\n   3. Non-invasive, superficial bladder cancer\n   4. Prostate cancer with a current Prostate-Specific Antigen (PSA) level \\\u003C 0.1 ng\u002Fmilliliter (mL)\n   5. Any curable cancer with a complete response (CR) of \\> 2 years duration.\n10. Neuropathy \\> grade 1 with the exception of neuropathy directly related to lymphoma (e.g., direct nerve compression from tumor).\n11. . Female who is pregnant, breast-feeding, or planning to become pregnant while enrolled in this trial or within 12 months after the last dose of epcoritamab; female subjects must also agree not to breastfeed during the entire trial and until 12 months after the last administration of study drug.\n12. Male who plans to father a child while enrolled in this trial or within 12 months after the last dose of epcoritamab.\n13. Contraindication to any of the individual drugs of the R-CHOP regimen.",{"count":258,"type":21},[25],"A Phase II, open-label, two-arm, multicenter study evaluating the combination of epcoritamab with R-CHOP chemotherapy in patients with newly diagnosed, aggressive B-cell non-Hodgkin lymphoma.",[419,208,420],"Non-Hodgkin's B-cell Lymphoma","Diffuse Large B-Cell Lymphoma (DLBCL)",[422,423,424],"Newly diagnosed B-cell lymphoma patients","Combination immunotherapy chemotherapy","epcoritamab R-CHOP lymphoma trial","2026-05-07",{"date":427,"type":35},"2026-05-15",{"date":429,"type":21},"2026-07-15",{"date":431,"type":21},"2029-07-31",{"name":433,"class":222},"Mwanasha Merrill, MD",{"id":435,"slug":436,"hasResults":12,"nctId":437,"briefTitle":438,"officialTitle":439,"acronym":440,"eligibilityCriteria":441,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":442,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":444,"conditions":445,"keywords":447,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":451,"lastUpdatePostDateStruct":452,"startDateStruct":454,"completionDateStruct":456,"leadSponsor":458,"locationsCount":83},"100634938","ai-based-predictive-and-interventional-system-for-early-detection-of-non-compliance-risks-with-oral-therapies-in-lymphoma-patients-100634938","NCT07546188","AI-based Predictive and Interventional System for Early Detection of Non-compliance Risks With Oral Therapies in Lymphoma Patients.","AI-based Predictive and Interventional System for Early Detection of Non-compliance Risks With Oral Therapies in Lymphoma Patients, Integrating the Complete Care Pathway and an Interoperable Clinical Interface With Algorithms Paired With Explainability Tools.","LNH-AI-Tools","Inclusion Criteria:\n\n* All patients aged 18 and over who are treated in the Haematology Department at the Grand Hôpital de Charleroi from November 2025 onwards\n* Treated for a lymphoma, Non Hodgkin\n* Capable of giving informed consent\n\nExclusion Criteria:\n\n* All other patients who did not meet the eligibility criteria",{"count":443,"type":21},210,"This research forms part of a continuous quality improvement initiative. It aims to assess patient compliance of oral therapies by artificial intelligence. It could overcome the limitations of current practices and enhance the responsiveness and accuracy of clinical interventions.",[28,446],"Care Coordination",[448,449,450],"Artificial intelligence","Non-Hodgkin lymphoma","Care pathway","2026-04-20",{"date":453,"type":35},"2026-04-22",{"date":455,"type":35},"2026-02-15",{"date":457,"type":21},"2029-02-15",{"name":459,"class":222},"Grand Hôpital de Charleroi",{"id":461,"slug":462,"hasResults":12,"nctId":463,"briefTitle":464,"officialTitle":464,"acronym":4,"eligibilityCriteria":465,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":466,"targetDuration":4,"studyType":22,"phases":468,"briefSummary":470,"conditions":471,"keywords":4,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":475,"lastUpdatePostDateStruct":476,"startDateStruct":478,"completionDateStruct":479,"leadSponsor":481,"locationsCount":83},"100629049","ehealth-mindfulness-based-music-therapy-intervention-for-patients-undergoing-stem-cell-transplantation-100629049","NCT07469592","eHealth Mindfulness-based Music Therapy Intervention for Patients Undergoing Stem Cell Transplantation","Inclusion Criteria:\n\n* ≥ 18 years of age\n* have a primary diagnosis of a hematologic malignancy (e.g., myelodysplastic syndrome \\[MDS\\], acute myeloid leukemia \\[AML\\], acute lymphoblastic leukemia \\[ALL\\], or non Hodgkin's Lymphoma \\[NHL\\])\n* have a treatment plan for a hematopoietic stem cell transplant\n* Speak English or Spanish\n\nExclusion Criteria:\n\n* history of severe psychiatric illness (e.g., psychosis, active suicidality, inpatient treatment in the past 12 months)\n* severe cognitive impairment (per the short portable mental status questionnaire)\n* hearing impairment\n* active alcohol or substance dependence within the past six months\n* participated in the prior pilot MBMT R61 phase\n* participated in music therapy or mindfulness programs in the past six months",{"count":467,"type":21},165,[469],"NA","The goal of this study is to test an electronic health (eHealth) mindfulness-based music therapy intervention to improve health-related quality of life and reduce symptom burden and disease activity in patients undergoing stem cell transplantation.",[472,237,473,474,28],"Stem Cell Transplantation","Leukemia, Myeloid, Acute","Precursor Cell Lymphoblastic Leukemia-Lymphoma","2026-04-10",{"date":477,"type":35},"2026-04-13",{"date":74,"type":21},{"date":480,"type":21},"2028-06-30",{"name":482,"class":222},"University of Miami",{"id":484,"slug":485,"hasResults":12,"nctId":486,"briefTitle":487,"officialTitle":487,"acronym":4,"eligibilityCriteria":488,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":489,"targetDuration":4,"studyType":22,"phases":491,"briefSummary":492,"conditions":493,"keywords":495,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":496,"lastUpdatePostDateStruct":497,"startDateStruct":498,"completionDateStruct":500,"leadSponsor":502,"locationsCount":83},"100587054","interrupting-sedentary-time-to-improve-cardiometabolic-health-and-toxicity-in-patients-with-lymphoma-receiving-chemotherapy-the-istand-trial-100587054","NCT06923397","Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial","Inclusion Criteria:\n\n* Ability to understand and the willingness to sign informed consent prior to any study- related procedures.\n* Patients diagnosed with lymphoma.\n* Will receive first line R-CHOP or POLA-R-CHP chemotherapy regimens, patients do not need to be within a certain timeframe from diagnosis.\n* Aged ≥18 years; due to the rarity of the disease in those \\\u003C18 years, this age bracket will not be included.\n* Engaging in ≤60-minutes of structured moderate or vigorous intensity exercise.\n* Have physician clearance to participate in exercise.\n* Speak English.\n* Willing to travel to Dana-Farber Cancer Institute for necessary data collection and exercise sessions.\n* Access to a phone that can receive text messages.\n\nExclusion Criteria:\n\n* Unstable comorbidities that prevent participation in moderate-to-vigorous intensity exercise. Patients with unstable comorbidities likely require supervised exercise for safety, and part of this study involves unsupervised exercise; therefore, for safety reasons, these persons are excluded.\n* Participate in more than 60 minutes of structured moderate-to-vigorous exercise per week over the last month. Excess additional exercise is a confounding factor in assessing the effect of the current interrupted sedentary time intervention.\n* Patients receiving treatment for other active malignancies (except basal cell carcinoma). This study is exclusively targeting lymphoma chemotherapy-related effects.\n* Patients currently taking weight loss drugs.\n* Subjects who in the opinion of the investigators may not be able to comply with the safety monitoring requirements of the study.\n* Unable to travel to DFCI Longwood campus for necessary data collection and chemotherapy infusions.",{"count":490,"type":21},24,[469],"This study aims to see if a 12-week exercise program designed to reduce long periods of inactivity is feasible in newly diagnosed lymphoma participants receiving R-CHOP or POLA-R-CHP chemotherapy treatments, and whether it can improve heart health and reduce chemotherapy drug side effects.",[70,316,28,494],"Sedentary Behavior",[70,239,316,28,207,494],"2026-04-09",{"date":477,"type":35},{"date":499,"type":35},"2025-06-05",{"date":501,"type":21},"2026-12-31",{"name":503,"class":222},"Dana-Farber Cancer Institute",{"id":505,"slug":506,"hasResults":12,"nctId":507,"briefTitle":508,"officialTitle":509,"acronym":4,"eligibilityCriteria":510,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":511,"targetDuration":4,"studyType":22,"phases":513,"briefSummary":514,"conditions":515,"keywords":517,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":519,"lastUpdatePostDateStruct":520,"startDateStruct":522,"completionDateStruct":524,"leadSponsor":526,"locationsCount":528},"100599308","phase-1-tln-121-in-relapsed-or-refractory-non-hodgkin-lymphomas-100599308","NCT07082803","TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas","An Open-Label, Multicenter, Phase 1 Trial to Evaluate the Safety, Pharmacokinetics, and Anti-Tumor Activity of TLN-121 as a Single Agent and in Combination With Other Anti-Lymphoma Agents, in Patients With Relapsed or Refractory Non-Hodgkin Lymphomas","Inclusion Criteria:\n\nDisease Characteristics\n\n1. Participant must have measurable disease at study entry\n2. Participants must have one of the following histologically documented hematologic malignancies:\n\n   1. Diffuse large B-cell lymphoma (DLBCL), not otherwise specified (DLBCL, NOS), Follicular lymphoma (FL) grade 3b, or transformed lymphoma from FL following at least 2 prior lines of therapy.\n   2. FL grade 1-3a that requires treatment following at least 2 prior lines of therapy.\n   3. The following Peripheral T-cell lymphoma (PTCL) subtypes that have relapsed after, or not responded to at least 1 prior systemic treatment regimen:\n\n      * Nodal T-follicular helper (Tfh) cell lymphoma angioimmunoblastic; Follicular helper T-cell lymphoma, angioimmunoblastic type (AITL).\n      * Nodal Tfh cell lymphoma, follicular type; Follicular helper T-cell lymphoma, follicular type.\n      * Nodal Tfh cell lymphoma, NOS; Follicular helper T-cell lymphoma, NOS.\n3. High-Grade B-Cell Lymphoma that has relapsed after, or not responded to at least 2 prior systemic treatment regimens.\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.\n\nExclusion Criteria:\n\n1. Participants must not have current central nervous system (CNS) involvement. Participants with past history of CNS involvement of lymphoma must have had CNS disease fully treated with no evidence of recurrence within 12 months.\n2. Participant must not have a history of autologous stem cell transplantation within 60 days or allogeneic stem cell transplantation within 90 days prior to the start of the study.\n3. Participant must not have a history of CAR T-cell or other T-cell targeting treatment ≤ 4 weeks prior to the start of the study.\n4. Participant must not have major surgery or severe trauma within 4 weeks prior to the start of the study.\n5. Participants must not have any condition, including significant acute or chronic medical illness, active or uncontrolled infection, or the presence of laboratory abnormalities, that places participants at unacceptable risk if participating in this study.\n6. Pregnant or lactating.\n7. Conditions that could affect drug absorption.",{"count":512,"type":21},180,[24],"The primary purpose of this study is to evaluate the safety, pharmacokinetics,, and preliminary anti-tumor activity of TLN-121 as a single agent and in combination with other anti-lymphoma therapies in patients with relapsed or refractory Non-Hodgkin Lymphomas",[70,516],"Lymphoma, Non Hodgkin",[518],"Relapsed or Refractory Non-Hodgkin Lymphomas","2026-03-25",{"date":521,"type":35},"2026-03-27",{"date":523,"type":35},"2025-06-23",{"date":525,"type":21},"2030-11",{"name":527,"class":42},"Treeline Biosciences, Inc.",12,{"id":530,"slug":531,"hasResults":12,"nctId":532,"briefTitle":533,"officialTitle":534,"acronym":535,"eligibilityCriteria":536,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":537,"targetDuration":4,"studyType":22,"phases":539,"briefSummary":540,"conditions":541,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":542,"lastUpdatePostDateStruct":543,"startDateStruct":544,"completionDateStruct":546,"leadSponsor":548,"locationsCount":551},"100308614","phase-2-canadian-profiling-and-targeted-agent-utilization-trial-captur-100308614","NCT03297606","Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)","Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR): A Phase II Basket Trial","CAPTUR","Inclusion Criteria: (screening step - non-drug specific)\n\n* Adult (≥ 18 yrs) patient with a histologically-proven incurable metastatic solid tumour (excluding primary brain tumours), multiple myeloma or B cell non-Hodgkin lymphoma (excluding CLL, SLL and HCL), for whom there is no standard treatment known to prolong life, or who has refused such treatment.\n* ECOG performance status 0-2.\n* Patients must have normal organ function as follows:\n\n  * Absolute neutrophil count: ≥ 1.5 x 10\\^9\u002FL for solid tumours; ≥ 1.0 x 10\\^9\u002FL for neurologic malignancies\n  * Platelets ≥ 75 x 10\\^9\u002FL (or ≥ 50 x 10\\^9\u002FL if bone marrow involvement by myeloma or lymphoma).\n  * Total bilirubin ≤ 1.5 x UNL.\n  * AST (SGOT)\u002FALT (SGPT) ≤ 2.5 x institutional upper limit of normal value unless liver metastases are present in which case they must be \\\u003C 5 x ULN;\n  * Serum creatinine ≤ 1.5 x UNL or calculated or measured creatinine clearance ≥ 50mg\u002Fmin\u002F1.73µ\\^2\n* Patients must have measurable disease\n* Results must be available from tumour genomic or protein expression testing (if used to identify genetic variants), from one of the initiatives \u002F groups listed in protocol Appendix VII. The test may have been performed on the primary tumour or a metastatic deposit (including bone marrow), or blood, in a diagnostic or research laboratory and must reveal a potentially actionable variant.\n* Patient consent (Main Study Consent for the screening step) must be appropriately obtained in accordance with applicable local and regulatory requirements. Each patient must sign a consent form prior to the screening step to document their willingness to participate\n* Patients must be accessible for treatment and follow-up. Patients registered on this trial must be treated and followed at the participating centre or a CCTG IND site. This implies there must be reasonable geographical limits (for example: 1 ½ hour's driving distance) placed on patients being considered for this trial.\n* Women\u002Fmen of childbearing potential must have agreed to use a highly effective contraceptive method.\n\nExclusion Criteria: (screening step - non-drug specific)\n\n* Patients with prior or concurrent malignancy whose natural history or treatment has the potential to interfere with the safety or efficacy assessment of the investigational regimen.\n* Patients with ongoing toxicity ≥ CTCAE grade 2, other than peripheral neuropathy or asymptomatic, corrected biochemical toxicities (e.g. hypothyroidism corrected by thyroid replacement), related to prior anti-tumour treatment. Patients with ongoing peripheral neuropathy of ≥ CTCAE grade 3 will be excluded.\n* Patients concurrently receiving any other anti-cancer therapy (cytotoxic, biologic, radiation, or hormonal other than for replacement) except for medications that are prescribed for supportive care but may potentially have an anti-cancer effect (e.g. megestrol acetate, bisphosphonates) or ongoing castration-intent therapy for prostate cancer. These medications must have been started ≥ one month prior to enrollment on this study. Patients may be on warfarin, low molecular weight heparin or direct factor Xa inhibitors, unless such therapies are prohibited by drug-specific ineligibility criteria.\n* Patients with known active progressive brain metastases. Patients with previously treated brain metastases are eligible, provided that the patient has not experienced a seizure or had a clinically significant change in neurological status within one month prior to screening. All patients with previously treated brain metastases must be stable (clinically and radiologically) for at least one month after completion of treatment and either off steroid treatment or only taking physiological doses of steroids prior to the screening step.\n* Patients with clinically significant pre-existing cardiac conditions, including uncontrolled or symptomatic angina, uncontrolled atrial or ventricular arrhythmias, or symptomatic congestive heart failure.\n* Patients with known left ventricular ejection fraction (LVEF) \\\u003C 40%.\n* Patients with stroke (including TIA) or acute myocardial infarction within three months prior to the screening step.\n* Patients with acute gastrointestinal bleeding within one month prior to the screening step.\n* Patients with any other clinically significant medical condition which, in the opinion of the treating physician, makes it undesirable for the patient to participate in the study or which could jeopardize compliance with study requirements including, but not limited to: ongoing or active infection, significant uncontrolled hypertension, or severe psychiatric illness\u002Fsocial situations.\n* Lactating and nursing women\n* Patients who do not meet drug-specific eligibility requirements for the drug selected by the treating physician.",{"count":538,"type":21},720,[25],"Cancer drugs which target the effects of abnormal gene changes are called 'targeted therapies'. This study, called PM.1 or CAPTUR, will include some targeted therapies that are currently available. The purpose of this study is to find out what are the effects on a patient and their cancer when they are given a targeted therapy drug that is specific to an abnormal gene change in their cancer.",[28,96,370],"2026-03-24",{"date":521,"type":35},{"date":545,"type":35},"2018-03-23",{"date":547,"type":21},"2027-01-31",{"name":549,"class":550},"Canadian Cancer Trials Group","NETWORK",10,{"id":553,"slug":554,"hasResults":12,"nctId":555,"briefTitle":556,"officialTitle":557,"acronym":4,"eligibilityCriteria":558,"healthyVolunteers":12,"sex":17,"minAge":559,"maxAge":4,"enrollmentInfo":560,"targetDuration":4,"studyType":22,"phases":562,"briefSummary":563,"conditions":564,"keywords":566,"overallStatus":135,"whyStopped":4,"lastUpdateSubmitDate":570,"lastUpdatePostDateStruct":571,"startDateStruct":573,"completionDateStruct":575,"leadSponsor":576,"locationsCount":83},"100621117","high-dose-vs-standard-ergocalciferol-for-vitamin-d-normalization-in-aggressive-non-hodgkin-lymphoma-100621117","NCT07366450","High-Dose vs Standard Ergocalciferol for Vitamin D Normalization in Aggressive Non-Hodgkin Lymphoma","Safety and Efficacy of High-Intensity Loading Dose Versus Standard Weekly Dosing of Ergocalciferol (Vitamin D2) for Vitamin D Normalization in Patients With Newly Diagnosed Aggressive Non-Hodgkin Lymphoma: A Randomized, Open-Label, Controlled Trial","Inclusion Criteria:\n\n* Age ≥ 20 years.\n* Newly diagnosed aggressive non-Hodgkin lymphoma, confirmed by histopathological examination according to the WHO Classification of Haematolymphoid Tumours, 5th edition, with an indication for standard first-line chemoimmunotherapy\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-3.\n* Serum 25-hydroxyvitamin D level \\\u003C 30 ng\u002FmL within 14 days prior to randomization.\n* Adequate organ function to receive full-dose standard chemotherapy.\n* Ability to provide written informed consent.\n\nExclusion Criteria:\n\n* Mild hypercalcemia (corrected Ca \\> 10.4 mg\u002FdL)\n* Hyperphosphatemia (PO4 \\> 4.5 mg\u002FdL)\n* History of urolithiasis associated with hypercalciuria or a diagnosis of primary hyperparathyroidism.\n* Chronic kidney disease stage 4 or higher (estimated glomerular filtration rate \\[eGFR\\] \\\u003C 30 mL\u002Fmin\u002F1.73 m²).\n* Inability to take oral medication, active gastrointestinal bleeding, or malabsorption syndrome.\n* Pregnancy or breastfeeding.\n* Prior systemic therapy for lymphoma.\n* Ongoing tumor lysis syndrome requiring urgent treatment.\n* Prior use of vitamin D supplements (ergocalciferol or cholecalciferol).\n\nWithdrawal Criteria:\n\n* Development of mild hypercalcemia.\n* Development of mild hypophosphatemia.\n* Development of hypervitaminosis D.\n* Occurrence of severe adverse events (AEs) or side effects for which the investigator considers discontinuation of the study drug necessary for patient safety.\n* Investigator's judgment that continued participation may pose a safety risk, such as the occurrence of serious infection, febrile neutropenia, or organ failure.\n* Non-adherence to study medication, defined as cumulative vitamin D₂ intake of less than 80% of the expected cumulative dose at the time of serum vitamin D assessment.\n* Participant withdrawal of consent to continue participation in the study.","20 Years",{"count":561,"type":21},52,[469],"The goal of this clinical trial is to evaluate whether a high-intensity loading dose of ergocalciferol (vitamin D2) can normalize blood vitamin D levels more rapidly and safely than standard weekly dosing in patients with newly diagnosed aggressive non-Hodgkin lymphoma. The study will also assess the safety of both dosing strategies.\n\nThe main questions it aims to answer are:\n\n* Does a high-intensity loading dose of ergocalciferol lead to faster normalization of serum 25-hydroxyvitamin D levels compared with standard weekly dosing?\n* Are there differences in safety and adverse events between the two dosing strategies?\n\nResearchers will compare a high-intensity loading dose regimen of ergocalciferol with a standard weekly dosing regimen to determine differences in vitamin D normalization and safety outcomes.\n\nParticipants will:\n\n* Be randomly assigned to receive either a high-intensity loading dose or a standard weekly dose of ergocalciferol (vitamin D2)\n* Receive standard first-line immunochemotherapy for aggressive non-Hodgkin lymphoma\n* Have blood tests to monitor vitamin D levels, calcium, phosphate, and safety parameters at scheduled visits\n* Be followed for treatment response, survival outcomes, and adverse events during and after therapy",[565,208],"Vitamin D 25-Hydroxylase Deficiency",[449,567,568,569],"Vitamin D deficiency","Overall survival","Efficacy","2026-01-16",{"date":572,"type":35},"2026-01-26",{"date":574,"type":21},"2026-02-01",{"date":431,"type":21},{"name":577,"class":222},"Phramongkutklao College of Medicine and Hospital",{"id":579,"slug":580,"hasResults":12,"nctId":581,"briefTitle":582,"officialTitle":583,"acronym":584,"eligibilityCriteria":585,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":586,"targetDuration":4,"studyType":22,"phases":588,"briefSummary":589,"conditions":590,"keywords":604,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":632,"lastUpdatePostDateStruct":633,"startDateStruct":635,"completionDateStruct":637,"leadSponsor":639,"locationsCount":641},"100517783","phase-1-a-dose-escalation-and-dose-expansion-study-of-intratumoral-onm-501-alone-and-in-combination-with-cemiplimab-in-patients-with-advanced-solid-tumors-and-lymphomas-100517783","NCT06022029","A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.","A Phase 1 Dose-Escalation and Expansion Study of Intratumorally Administered ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas","ON-5001","Inclusion Criteria:\n\n1. Ability to understand and willingness to sign written informed consent before performance of any study procedures\n2. Age ≥ 18 years\n3. Participants with solid tumors or lymphomas, confirmed by available histopathology records or current biopsy, that are advanced, nonresectable, or recurrent and progressing since last antitumor therapy, and for which no alternative standard therapy exists.\n4. Participants must have a minimum of one injectable and measurable lesion.\n5. Participants with prior Hepatitis B or C are eligible if they have adequate liver function\n6. Participants with human immunodeficiency virus (HIV) are eligible if on established HAART for a minimum of 4 weeks prior to enrollment, have an HIV viral load \\\u003C400 copies\u002FmL, and have CD4+ T-cell (CD4+) counts ≥ 350 cells\u002FuL\n7. Adequate bone marrow function:\n8. Adequate liver function\n\nExclusion Criteria: Patients will be excluded from this study if they meet any of the following criteria (Part 1a and Part 1b).\n\n1. Other malignancy active within the previous 2 years except for basal or squamous cell skin cancer, superficial bladder cancer, or carcinoma in situ of the cervix or breast that has completed curative therapy.\n2. Major surgery within 4 weeks before the first dose of study drug.\n3. Brain metastases that are untreated or in the posterior fossa or involve the meninges. Participants with stable or previously treated progressing brain metastases (except in the posterior fossa or involving the meninges) may be permitted in a case-by-case basis at the Sponsor's discretion.\n4. Prolongation of corrected QT (QTc) interval to \\>470 millisecond (ms) for males and females when electrolytes balance is normal.\n5. Females who are breastfeeding or pregnant at screening or baseline\n6. Females of childbearing potential that refuse to use a highly effective method of contraception.\n7. Has uncontrolled or poorly controlled hypertension as defined by a sustained BP \\> 9. Has received prior investigational therapy within 5 half-lives of the agent or 4 weeks before the first administration of study drug, whichever is shorter.\n8. Has had any major cardiovascular event within 6 months prior to study drug 10. Has known hypersensitivity to any component in the formulation of ONM-501\n9. Has an active infection requiring systemic treatment\n10. Is participating in another therapeutic clinical trial\n\nAdditional Exclusion Criteria for ONM-501 in Combination with cemiplimab (Part 1b)\n\n1. Has known hypersensitivity to any component in the formulation of cemiplimab\n2. Has any active or recent history of a known or suspected autoimmune disease or recent history of a syndrome that required systemic corticosteroids (\\>10 mg daily prednisone equivalent)\n3. Has a condition requiring systemic treatment with corticosteroids",{"count":587,"type":21},168,[24],"A phase 1, multicenter, open label, non-randomized dose escalation and dose expansion study to examine the maximum tolerated dose, (MTD), minimum effective dose (MED) and\u002For recommended dose for expansion (RDE) of intratumoral ONM-501 as monotherapy and in combination with a PD-1 checkpoint inhibitor in patients with advanced solid tumors and lymphomas.",[591,592,593,28,594,595,596,597,598,599,600,601,602,603],"Triple Negative Breast Cancer","Diffuse Large B Cell Lymphoma","Follicular Lymphoma","Mantle Cell Lymphoma","Bladder Cancer","Uveal Melanoma, Recurrent","Cervix Cancer","Carcinoma in Situ","Head and Neck Squamous Cell Carcinoma","Skin Cancer","Metastatic Cancer","Tumor, Solid","Tumor Recurrence",[605,70,606,607,608,609,610,611,600,612,613,614,615,616,617,618,619,620,621,622,623,624,625,626,627,628,629,630,631],"Solid tumors","ONM-501","STING","Intra-tumoral","HNSCC","Breast Cancer","Melanoma","cemiplimab","Libtayo","DLBCL","bladder cancer","cervical cancer","metastases","immunotherapy","ICI","TNBC","Triple Negative","mTNBC","anti-PD-1 antibody","BRCA1","BRCA2","anti-PD-L1","uveal","NHL","Mantle Zone lymphoma","FL","stimulator of interferon genes","2025-12-18",{"date":634,"type":35},"2025-12-24",{"date":636,"type":35},"2023-10-13",{"date":638,"type":21},"2026-08-29",{"name":640,"class":42},"OncoNano Medicine, Inc.",16,{"id":643,"slug":644,"hasResults":12,"nctId":645,"briefTitle":646,"officialTitle":646,"acronym":4,"eligibilityCriteria":647,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":648,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":650,"conditions":651,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":653,"lastUpdatePostDateStruct":654,"startDateStruct":655,"completionDateStruct":657,"leadSponsor":659,"locationsCount":83},"100087542","clinical-and-pathologic-studies-in-non-hodgkins-lymphoma-and-hodgkins-disease-100087542","NCT00398177","Clinical and Pathologic Studies in Non-Hodgkin's Lymphoma and Hodgkin's Disease","Inclusion Criteria:\n\n* Diagnosis of Hodgkin's disease or non-Hodgkin's lymphoma, any cellular classification, any stage, any grade.\n* Adult or pediatric patients receiving lymph node excision for purposes other than cancer therapy (i.e. tonsillectomy, sleep apnea).\n* A routine procedure for tissue collection is planned.\n* Ability to understand and the willingness to sign a written informed consent.\n\nExclusion Criteria:\n\n* Patients without NHL or Hodgkin's disease",{"count":649,"type":21},9999,"The purpose of this study is to characterize the molecular and cell biology of the tumor cells in lymphoma.",[28,652],"Hodgkin's Disease","2025-12-17",{"date":634,"type":35},{"date":656,"type":4},"1999-01",{"date":658,"type":21},"2099-01",{"name":660,"class":222},"Stanford University",{"id":662,"slug":663,"hasResults":12,"nctId":664,"briefTitle":665,"officialTitle":666,"acronym":4,"eligibilityCriteria":667,"healthyVolunteers":668,"sex":17,"minAge":18,"maxAge":669,"enrollmentInfo":670,"targetDuration":4,"studyType":93,"phases":4,"briefSummary":672,"conditions":673,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":676,"lastUpdatePostDateStruct":677,"startDateStruct":679,"completionDateStruct":681,"leadSponsor":683,"locationsCount":83},"100104689","family-study-of-lymphoproliferative-disorders-100104689","NCT00626496","Family Study of Lymphoproliferative Disorders","Genetic Epidemiology of Lymphoproliferative Disorders","At least 2 living, blood related relatives, affected with a lymphoproliferative disorder.",true,"100 Years",{"count":671,"type":21},3000,"Blood and lymph node cancers can begin in either the lymphatic tissues (as in the case of lymphoma) or in the bone marrow (as with leukemia and myeloma), and they all are involved with the uncontrolled growth of white blood cells. There are many subtypes of these cancers, e.g., chronic lymphocytic leukemia and non-Hodgkin lymphoma. Since there is evidence that these cancers cluster in families, this study aims to understand how genetics and environmental exposures contribute to the development of these cancers.",[28,674,292,675,96],"Leukemia, Lymphocytic, Chronic, B-Cell","Monoclonal B-Cell Lymphocytosis","2025-10-09",{"date":678,"type":35},"2025-10-14",{"date":680,"type":35},"2004-04-01",{"date":682,"type":21},"2029-12-31",{"name":684,"class":222},"Mayo Clinic",{"id":686,"slug":687,"hasResults":12,"nctId":688,"briefTitle":689,"officialTitle":689,"acronym":690,"eligibilityCriteria":691,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":692,"targetDuration":4,"studyType":22,"phases":694,"briefSummary":695,"conditions":696,"keywords":698,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":702,"lastUpdatePostDateStruct":703,"startDateStruct":705,"completionDateStruct":707,"leadSponsor":709,"locationsCount":83},"100526337","evaluation-of-the-role-of-connected-scales-in-the-therapeutic-care-of-hematology-patients-100526337","NCT06133426","Evaluation of the Role of Connected Scales in the Therapeutic Care of Hematology Patients","BTP","Inclusion Criteria:\n\n* Patient aged 18 and over (male or female)\n* Patient suffering from aggressive non-Hodgkin's lymphoma or multiple myeloma with a plan for systemic chemotherapy or having started two cycles or less or patient with the need for therapeutic intensification under the cover of autograft in the context of myeloma or lymphoma\n* Patient who can be contacted by telephone during their participation in the research\n* Patient able to return home at the end of their initial hospitalization\n* Patient affiliated to social security\n* Patient able to read and speak French\n* Patient having signed free, informed and written consent\n\nExclusion Criteria:\n\n* Patient with an estimated life expectancy \\\u003C 3 months\n* Patient with moderate to severe cognitive impairment (assessed by MMSE \\\u003C 20)\n* Patient with a psychiatric or physical disability that does not allow the use of the device\n* Patient with a pacemaker\n* Patient participating in another intervention research project\n* Pregnant patient\n* Patient deprived of liberty\n* Patient under legal protection (guardianship or curatorship)",{"count":693,"type":21},30,[469],"In this research, we will evaluate the feasibility of following by remote monitoring, using a connected scale, in hematology patients suffering from myeloma or lymphoma and requiring treatment with chemotherapy. 30 patients will be included in the research and will all use a connected scale for the duration of their participation (7 weeks +\u002F- 1 week). During their participation, patients will be asked to weigh themselves once a day, ideally at a set time. Patient data will be accessible by the medical team via a remote monitoring platform.\n\nAlerts will be generated in the event of abnormal development of certain clinical parameters (weight, heart rate, etc.) allowing early treatment to be implemented by the medical team.\n\nAt the end of their participation, we will evaluate patients' support and perception of this tool, as well as the healthcare consequences of the alerts generated by the remote monitoring platform.",[28,697],"Myeloma Multiple",[699,700,701],"Hematology","Connected scale","Remote monitoring","2025-09-09",{"date":704,"type":35},"2025-09-15",{"date":706,"type":35},"2025-09-04",{"date":708,"type":21},"2026-05",{"name":710,"class":222},"Assistance Publique - Hôpitaux de Paris"]